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CORRELATION OF PLASMA OSTEOPONTIN WITH RADIOLOGICAL 
GRADING IN PATIENTS WITH OSTEOARTHRITIS IN THE KNEE JOINT 
 
ABSTRACT: 
 Objectives and aims of the study:  
 To correlate plasma osteopontin level with radiological grade in patients with 
knee osteoarthritis (OA) and to correlate plasma osteopontin level with serum 
hyaluronic acid in patients with knee OA, thereby to assess, if osteopontin contributes 
to the pathogenesis of the degenerative process of OA by stimulating MMP13 and 
increase hyaluronic acid levels in serum.   
 
Materials and methods:  
 60 patients with varying grades of radiological evidence of OA in the knee 
joint and 30 healthy subjects as controls were enrolled in the study. Anteroposterior 
knee radiographs, in standing position were taken to determine the disease severity of 
the affected knee joint. The radiographic grading of OA in the knee joint was 
performed by using the Kellgren–Lawrence grading (K/L). Osteopontin levels in the 
plasma and hyaluronic acid levels in the serum were measured using enzyme-linked 
immunosorbent assay and compared. 
 
Results:  
 The mean plasma osteopontin concentration of the knee OA patients was 
significantly higher compared with that of healthy controls (984.91+/-804 pg/mL vs 
611.05+/-207.59 pg/mL, p=0.014).  The plasma osteopontin levels significantly 
correlated with severity of disease (r=0.349, p=0.006). The mean serum hyaluronic 
acid concentration of the knee OA patients was significantly higher compared with 
that of healthy controls (2.58+/−0.90ng/mL vs 1.87+/−0.48 ng/mL). The serum 
hyaluronic acid level significantly correlated with K/L grades (r=0.358, p=0.005). The 
plasma osteopontin and serum hyaluronic acid levels were compared in relation to 
radiological K/L grades 2, 3, 4 among the cases and was found to have statistically 
significant higher concentrations as the grade increased with p= 0.022 for osteopontin 
and p=0.006 for hyaluronic acid. 
 
Conclusion:  
 Osteopontin in plasma and Hyaluronic acid in serum are related to progressive 
joint damage in knee OA. Hence in the present study statistically significant increase 
in concentration of both osteopontin & hyaluronic acid with respect to radiological 
grade and a positive correlation between osteopontin and K/L grade & hyaluronic acid 
and K/L grade implies that osteopontin has a significant role in activating MMP-13 
causing degradation of articular cartilage and release of HA into the circulation in OA. 
Hence osteopontin and hyaluronic acid can be used in combination as biomarkers to 
assess the severity of the disease. 
 
Keywords:  
 Osteoarthritis, Osteopontin, Hyaluronic acid, Kellgren-Lawrence grading  
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INTRODUCTION 
 
 Osteoarthritis(OA) is a “universal disorder” affecting both sexes and all 
races and is the commonest of all joint diseases. OA is a  “strongly age –related 
disorder defined by focal lesions of the articular cartilage, combined with a 
hypertrophic reaction in the subchondral bone and new bone formation at the 
joint margins with chronic nonspecific synovial inflammation”. OA is a 
chronic degenerative joint disease characterised by progressive destruction of 
articular cartilage with varying degrees of severity within a given joint. 
 
 To identify patients with a high risk for destructive OA and to monitor 
drug efficacy, most sensitive techniques other than “plain x-rays” are required. 
Hence for investigation and monitoring of patients with OA, specific and 
sensitive biochemical markers which reflect abnormalities in the turnover of 
bone, cartilage and synovial tissues may be useful.                                                                                                                   
 
  “Osteopontin” is one of the major noncollageneous bone matrix 
proteins produced by various cells like activated T cells, macrophages, 
osteoblasts and chondrocytes. Osteopontin may be involved in the pathogenesis 
of osteoarthritis, at the molecular level1, contributing to progressive 
degeneration of articular cartilage. 
 
 Osteopontin stimulates MATRIX METALLOPROTEINASE 13 
(MMP-13), which causes bone destruction by degrading the major component 
of bone matrix and results in the release of hyaluronic acid into circulation. 
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The present study is undertaken: 
1. to unravel the role of  plasma osteopontin levels as a biomarker for OA 
and to correlate the plasma concentration of osteopontin in patients with 
primary knee OA with the radiological grading. 
2. to understand the contribution of osteopontin in accelarating the 
pathogenesis of OA, anticipated to enhance serum hyaluronic acid 
levels. 
                 
  
Review of Literature 
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REVIEW OF LITERATURE 
INTRODUCTION 
 OA is a “chronic degenerative disease of the joints characterised by 
progressive softening and disintegration of articular cartilage, hypertrophy of 
bone at the margins (osteophytes), cyst formation, subchondral  sclerosis and a 
range of morphological and biochemical alterations of the capsule and synovial 
membrane6   of the joint”.  Usually, it is distributed asymmetrically and 
localised to only one part of any joint and is often associated with “abnormal 
loading rather than frictional wear and tear”. 
 
 OA is neither primarily an inflammatory disorder nor purely a 
degenerative disorder. OA is a dynamic phenomenon which shows features of 
both destruction and repair. Cartilage softening and disintegration lead to 
hyperactive new bone formation and remodelling. The secondary factors which 
influence the progress of this disorder include appearance of calcium 
containing crystals in the joint, ischemic changes leading to osteonecrosis in 
the subchondral bone in elderly people causing joint instability. 
 
 OA is a disease process that affects the entire joint   that includes 
cartilage, synovial membrane, subchondral bone, ligaments, and peri -articular 
muscles. OA arises from both systemic and local factors (biochemical mediated 
events) producing a condition with definable morphological and clinical 
outcomes2. 
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 OA may be classified into primary of unknown etiology and secondary 
with identifiable cause. Common causes of secondary OA include – 
 
 1. Metabolic (calcium crystal deposition, acromegaly) 
 2. Traumatic (joint injury) 
 3. Anatomic (congenital hip dislocation)  
 4. Inflammatory disorder (septic arthritis, ankylosing spondylitis). 
 
 Usually, secondary OA arises due to inflammatory cause with release of 
degenerative enzymes from synovium attributing to mechanical attrition of 
biomechanically altered extracellular matrix. 
 
ETIOLOGY 
 The factors affecting degree of risk of developing OA are age, gender, 
obesity, joint location, genetic predisposition. 
 
1. AGE – the most common risk factor which strongly correlate with OA. 
Chondrocytes undergo age-related decrease in mitotic and synthetic 
activity. They show a decreased response to anabolic growth factors and 
synthesize less uniform large aggregating proteoglycans with fewer link 
proteins. Age is an independent risk factor as it predisposes articular 
chondrocytes to apoptosis, because in aged cartilage there is higher level of 
expression of pro -apoptotic genes (Fas, Fas L, caspase - 8, p 53)3. 
 
2. GENDER – Women develop OA twice more commonly than men after the 
age of 50 due to postmenopausal oestrogen deficiency. Nuclear oestrogen 
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receptors are found in articular chondrocytes of humans8 and human growth 
plate chondrocytes. Wluka & colleagues9 reported that women using long 
term ESTROGEN REPLACEMENT THERAPY (ERT) presented with 
more knee cartilage than controls. 
 
3. OBESITY – Another important risk factor for OA is obesity. Increased risk 
of   OA knee is associated with increased body mass index (BMI) in both 
men and women. In women due to more total body fat, they tend to develop 
OA more commonly than men. This is because adipose tissue is a 
metabolically active contributor to inflammatory cascades leading to 
increased synthesis of pro-inflammatory cytokines- IL-1&6, TNF, leptin , 
adiponectin , resistin4,5. Hence by reducing BMI, symptoms and 
radiological progression can be reduced. 
 
4. JOINT LOCATION – OA most commonly occur in weight-bearing joints 
and joint specific age related viability in articular cartilage explains why 
OA is more common in knee and hip, than ankle, as age advances. 
 
5. GENETIC PREDISPOSITION – Genetic contribution to the 
pathogenesis of OA is difficult to analyse because of the prevalence in the 
general population and extensive clinical heterogeneity. Increased risk of 
OA has been associated with multiple gene variations6 caused by mutations 
in genes coding for the various types of collagen. The types of collagen 
expressed in cartilage includes types II, IV, V, VI and CARTILAGE 
OLIGOMERIC  MATRIX PROTEIN (COMP)6. The haplotype of 
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VITAMIN D RECEPTOR (VDR) plays a vital role in controlling bone 
mineral density and appears to be associated with a twofold risk of knee 
OA7. Loughlin & colleagues provided evidence that the IL-1 gene cluster 
harbours susceptibility to knee OA. 
 
 Studies of differential gene expression help to elucidate the pathogenesis 
for arriving with newer therapies and helps in 
 
1. Identification of unique biomarkers for diagnosis and management of 
OA. 
2. Identification of candidate susceptibility genotypes like polymorphic 
variations of cytokines or growth factors that may predispose to disease 
progression6. 
 
PATHOGENESIS 
CHANGES IN OSTEOARTHRITIS 
Morphologic changes  
 In early OA articular cartilage becomes irregular and roughened, in the 
synovial tissues, superficial clefts become apparent. As disease progresses 
clefts deepen and there is an increase in the surface irregularities and articular 
cartilage ulcerates exposing the underlying bone. On further progression of 
disease, the joint articulates on exposed bone causing thickening of bone and 
eburnation which becomes more metabolically active in response. 
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Early Reparative, Proliferative & Hypertrophic changes 
 In healthy cartilage, chondrocytes are quiescent but proliferate in 
clusters in the early stages of OA, associated with, expression of high levels of 
matrix proteins like type II collagen, aggrecan, stem cell markers and markers 
of hypertrophic differentiation 10. Chondrocyte clusters are thought to 
contribute to the pathogenesis of OA and its progression through release of 
matrix degrading enzymes, inflammatory cytokines and growth factors which 
further affect the surrounding chondrocytes and joint tissues11. 
 
Osteophyte formation 
 Osteophytes are newly formed fibrocartilage and bone. They are 
commonly formed at the peripheral margins of joints between the cartilage and 
periosteum interface. Osteophytes contribute to the stability of joints12, 13. As 
OA progresses the abundant osteophytes formed can limit movement and 
become painful. 
 
Hypo-cellularity 
 In aging cartilage there is a reduction in cell number due to reduced 
synthesis, which is an important contributing factor to the initiation and 
progression of OA. Apoptosis in chondrocytes can be triggered by factors 
which are involved in initiation and progression of arthritis viz., mechanical 
damage or injury, changes in cell matrix interactions, oxidative stress due to 
nitric oxide or reactive oxygen species, impaired mitochondrial function, signal 
transduction pathways i.e., CD95/CD95 ligand. Finally caspases are 
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accelerated to complete apoptosis. To prevent secondary OA following injury, 
inhibition of apoptosis by interfering with caspase activation following injury, 
as a chondro protective intervention is being explored. Hence autophagy can be 
protective in cartilage and its reduction in OA corresponds with an increase in 
the release of apoptotic markers14. 
 
ALTERATIONS IN CARTILAGE MATRIX METABOLISM 
 In early OA, there is a significant increase in the water content of 
articular cartilage which causes the tissues to swell and cause biomechanical 
alterations in these tissues. This suggests that there has been weakening of 
collagen network. Type II collagen fibres have smaller diameter than that in 
normal cartilage and the normal tight weave in the mid zone is slackened and 
distorted15 in OA. 
 
 In later stages of OA within the extracellular matrix, type I collagen 
concentration increases and the proteoglycan concentration falls to less than or 
equal to 50 per cent, with less aggregation and shorter glycosaminoglycan side 
chains16, 17. The ratio of chondroitin-4-sulfate to chondroitin-6-sulfate increases 
and  that of keratan sulphate concentration decreases reflecting the synthesis by 
chondrocytes of a proteoglycan profile which is typical of immature cartilage. 
As the disease progresses the proteoglycan concentration in the cartilage 
diminishes progressively18. 
 
 The first step in cartilage degradation is the decrease in density of 
proteoglycan which is at least partly reversible19. The decreased proteoglycan 
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density opens up the cartilage porosity, increases the permeability to 
collagenases/ proteases, exposing collagen fibrils. This initiates a vicious cycle 
of positive feedback loops which further promote cartilage degradation. For 
example, epitopes on collagen become accessible to the cell surface DDR2 
receptor which increases MMP13 production by the activation of the 
Ras/Raf/MEK/ERK and p38 signal cascades20. The partially digested matrix 
has a cytokine like activity that enhances inflammatory response and promotes 
matrix degradation. The destruction of collagenous cartilage is thought to be 
irreversible. 
 
 Calcium crystals are commonly found in the cartilage of the elderly and 
crystal arthropathy often coexists with OA. PYROPHOSPHATE (PP) is 
produced from adenosine triphosphate (ATP) by the exoenzyme nucleoside 
pyrophosphohydrolase21. Synovial fluid of OA patients showed high levels of 
PP which directly correlate with the severity of joint damage22. Normal adult 
cartilage secretes little of PP but the young or proliferating chondrocytes are 
the major source of PP. This increased PP secretion in OA cartilage might 
indicate the increased chondrocyte metabolic activity towards the matrix 
repair22. The CALCIUM PYROPHOSPHATE DEHYDRATE (CPPD) may 
alter the biomechanical properties of the cartilage extracellular matrix which 
leads to cartilage breakdown. Hemochromatosis (hemosiderin), Wilson’s 
disease (copper), gouty arthritis (monosodium urate crystals), the CPPD crystal 
deposition disease are examples of condition which may alter the cartilage 
extracellular matrix leading to either direct or indirect chondrocyte injury and 
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thereby increasing the stiffness of the tissue and precipitating the development 
of OA. 
 
Metabolic changes  
 Early OA is characterised by increased synthesis of proteoglycans, 
hyaluronate, collagen, noncollagenous proteins and cell replication18, 22. The 
activation of chondrocytes is thought to be an attempt to repair the cartilage 
matrix which yields a matrix of inferior quality which is more susceptible to 
degradation23. Both anabolic and catabolic processes increase as cells attempt 
to repair and maintain tissue integrity and it is this imbalance between synthesis 
and degradation which is thought to be important in the pathogenesis of OA22. 
 
 In later stages of OA, there is a decrease in cell number and in the 
synthesis of matrix with lowered quality along with the inability to blend the 
hyaluronic acid 16 , 24. In addition there is an activation of matrix degrading 
enzymes with an overall decrease in concentration of enzyme inhibitors such 
as, TISSUE INHIBITORS of METALLOPROTEINASES (TIMP), in later 
stages of OA. The complex interaction between matrix synthesis and 
degradation explains why OA is slowly progressive, static by morphologic 
criteria, finally resulting in the overall degradation of cartilage matrix. 
 
CONTRIBUTING FACTORS FOR OSTEOARTHRITIS 
A. Anabolic factors and cartilage repair 
i. TRANSFORMING GROWTH FACTOR – BETA (TGF –β) – It is 
essential for the formation and maintenance of cartilage. It affects 
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cartilage homeostasis by enhancing stem cell chondrogenesis to increase 
the pool of cells available for cartilage synthesis, thereby increase 
matrix production in existing chondrocytes. 
 
TGF-β increases synthesis of anti - catabolic factors such as TIMPs that 
inhibit activation of latent proteinases in cartilage. TGF-β attenuates the 
cellular response to inflammatory cytokines (IL-1, TGF- β, TNF) 25. In 
aging cells TGF-β can have opposing effects by activating MMP-13 and 
inducing terminal hypertrophic differentiation in chondrocytes26. 
 
ii.  BONE MORPHOGENETIC PROTEINS (BMP) – structurally 
related to TGF-β, activate different set of receptors and intracellular 
signalling molecules. It influences all stages of embryonic 
chondrogenesis. Recent genetic evidence reports that, impaired BMP 
signalling with the utmost progress for BMP-14, affects OA 
susceptibility27, 28. There is a reduction in BMP- 7 in OA cartilage with 
possible regulation occurring through both inhibitory microRNA29 and 
promoter methylation30. Supplementation of BMP-7 has reduced 
arthritis in experimental animals and has been proven safe in phase – I 
clinical trial. BMP can also enhance terminal differentiation and 
hypertrophy in chondrocytes, the processes that are hallmarks of OA 
progression. 
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B. Catabolic factors and cartilage degradation 
 Cartilage remodelling and new matrix synthesis involves a degree of 
proteolysis which occurs via induction of an array of proteases mainly matrix 
metalloproteinases (MMPs). IL-1, TNF stimulate the synthesis and secretion of 
proteases and MMPs in OA19 (Figure-1). IL -1 is synthesized by chondrocytes 
as an autocrine activity and by mononuclear cells and synovial lining cells in 
the inflamed joint. IL -1and TNF stimulate the latent forms of the enzymes viz., 
collagenase, stromelysin and gelatinase, including aggrecanase and TISSUE 
PLASMINOGEN ACTIVATOR (TPA) 31. Plasminogen either enters the 
matrix by diffusion from synovial fluid or synthesized by the chondrocytes. 
TPA converts plasminogen to plasmin, a serine proteinase which activates 
latent cartilage degrading enzymes. HYPOXIA- INDUCIBLE FACTOR 2 
alpha (Hif2α) is gaining increasing attention as a downstream mediator of IL-1 
and TNF induced cartilage degradation32, 33. In OA cartilage Hif2 α is a 
transcription factor that is strongly up regulated which directly induces the 
expression of many cartilage degrading enzymes like MMPs- 1, 3, 9, 12 and A 
DISINTEGRIN AND METALLOPROTEINASE with 
THROMBOSPONDIN motif (ADAMTS-4) and ADAMTS-5 indirectly. A 
high level of Hif2α decreases the protective role of autophagy and increases the 
extent of cell death and activates the RUNT- RELATED TRANSCRIPTION 
FACTOR 2 (RUNX2) and INDIAN HEDGE HOG pathway which further 
contribute to cartilage matrix degradation. The different classes of proteinases 
activated by these cytokines in OA are discussed below in detail. 
  
 
 
 
 
FIGURE-1-PATHOGENESIS OF OSTEOARTHRITIS 
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Classes of Proteinases (Metalloproteinases, Serine and Cysteine proteases, 
Aggrecanases) 
 In OA there is a marked increase in the synthesis and secretion of matrix 
degrading enzymes by chondrocytes18,34. There are four classes of proteases 
grouped by the catalytic mechanisms of peptide bond cleavage  
1. Metalloproteinases 
2. Cysteine proteinases 
3. Serine proteinases 
4. Aspartyl proteinases 
 Out of these the first three have clearly defined roles in the degradation 
of cartilage during the progression of OA. 
 
Metalloproteinases 
 Metalloproteinases have enzymatic site which requires zinc metal ion 
for activity. Cartilage contains two families of metalloproteinases – ADAMTSs 
and MMPs. Early cartilage degeneration in OA is due to metalloproteinase 
enzymatic activity. Both families of metalloproteinases are up-regulated and 
highly expressed in OA cartilage at sites of lesion. As the MMPs and 
ADAMTSs play major role in the degradation of cartilage extracellular matrix 
and these are now acting as candidate targets for disease modification. 
 
 The control of metalloproteinase activity is complex in OA with 
regulation occurring at three different levels – synthesis and secretion, 
activation of latent enzyme and inactivation by proteinase inhibitors35. After 
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stimulation with cytokine and growth factor signalling metalloproteinases 
transcription is induced and its stability and translation are regulated by 
microRNAs. For example, microRNA -27b regulates MMP-13 expression36. 
The microRNA-140 levels are decreased in OA which reduces its repression of 
ADAMTS-537. IL-1 and TGF-beta control these microRNAs, which are 
involved in the pathogenesis of OA by affecting transcript stability and protein 
translocation. Once translated into proteins all MMPs are expressed as inactive 
zymogens which require further processing for complete proteolysis. Most 
MMPs contain N-terminal pro-domain that blocks or inhibits the catalytic site. 
The primary MMP activators are serine and cysteine dependent proteases 
(plasminogen or pro-protein convertases and cathepsin B respectively) as well 
as membrane-type MMPs38. Activated MMPs then can be inactivated non-
specifically by α2 macroglobulin and more specifically by the tissue inhibitor 
of metalloproteinase.  
 
 Based on their substrate specificities MMPs have been divided into three 
groups. 
 
1. Collagenases – cleave all three chains of native triple helical 
collagen. 
2. Gelatinases – cleave denatured collagen 
3. Stromelysins – have broader substrate specificities39. 
 
 There is considerable overlap in substrate between these classifications 
for (eg) MMP-1 (interstitial collagenases), MMP-3 (stromelysin1) and MMP-
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13 (collagenase-3) all are capable of cleaving aggrecan core protein40. In 
addition to collagen, MMPs can degrade other cartilage extracellular matrix. 
MMPs can rapidly destroy cartilage completely if combined with plasmin 
which has the capability of activating many MMPs. 
 
Collagenases 
 Collagenases cleave typically, the triple helical collagen allowing 
further degradation by other proteases. The first irreversible step in the 
pathogenesis of OA is the degradation of collagen which significantly reduces 
the mechanical properties of cartilage. The best studied MMPs capable of 
cleaving native collagen are MMP-13 and MMP-1 of which, MMP-13 may be 
the most important in OA because it preferentially degrades type II collagen41. 
Expression of MMP-13 is greatly increased in OA42 and overall collagenase 
activity markedly increases in human  OA cartilage cultures, suggesting that it 
is a major progressive factor in OA  by degrading the cartilage matrix 43. The 
resultant collagen fragments may be susceptible to further cleavage by other 
enzymes like MMP-2 (gelatinaseA), MMP-3, MMP-9 (gelatinaseB) and 
cathepsin B (a cysteine proteinase). 
 
Aggrecanases 
 The aggrecanases belong to a family of extracellular proteases known as 
ADAMTS44. The two major aggrecanases involved in cartilage degradation are 
ADAMTS-4, predominantly associated with aggrecan degradation in human 
OA and ADAMTS-5 is more important in mouse45-47. The G1 region of 
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aggrecan is highly resistant to proteases but a glutamate-alanine bond within 
the extended region between G1 and G2 is susceptible to proteolysis to further 
degradation. ADAMTS-4 and ADAMTS-5 activity is detected in joint capsule 
and synovium and may be up-regulated in synovium through posttranslational 
processing. In addition several MMPs are also capable of cleaving aggrecan in 
vitro (MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-13, MMP-
28 ). ADAMTS-7 and ADAMTS-12 both bind to and degrade COMP – a 
prominent non-collagenous protein in cartilage and the latter is up-regulated in 
OA cartilage48, 49. 
 Several lysosomal enzymes that cleave both hyaluronic acid and 
chondroitin-6-sulfate have been implicated in OA progression .In the human 
genome there are about  6 or 7 potential hyaluronidases of which 
hyaluronidase-1, hyaluronidase-2, hyaluronidase-3 are likely to be active in 
cartilage50. The decrease in chondroitin sulphate chain length in OA cartilage, 
may be due to digestion by synovial fluid hyaluronidase which diffuse into the 
matrix as the permeability increases. The concentration of hyaluronic acid in 
OA cartilage is low in spite of the increased rate of synthesis of hyaluronic 
acid. These degradative enzymes disrupt the proteoglycan aggregate. The early 
change that occurs due to the MMP induced tissue degradation is the thinning 
of collagen fibres, loosening of the tight collagen network and the consequent 
cartilage matrix swelling in OA. 
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Enzyme Inhibitors (Tissue Inhibitor of Metalloproteinases, Plasminogen 
Activator Inhibitor – 1) 
 The balance between the active and the latent enzymes is controlled by 
two enzyme inhibitors – tissue inhibitor of metalloproteinases (TIMP) and 
plasminogen activator inhibitor -1 (PAI- 1)51. Under the regulation of TGF-β 
the synthesis of these two enzymes are increased51. If these enzyme 
concentrations decrease along with active enzyme concentration then the 
matrix degradation increases. Genes that showed increased expression in OA 
are MMP-2, MMP-9, MMP-13, MMP-16, MMP-28, ADAMTS-2, 12, 14, 16 
and TIMP-3. Genes with decreased expression in OA are MMP-1, 3, 10 , 
ADAMTS-1, 5, 9, 15 and TIMP1 and 452. These explain the complexity of the 
events that occur in the extracellular matrix regarding regulation of tissue 
degrading enzymes. 
 
ALTERATIONS IN MATRIX SYNTHESIS 
 The changes in the extracellular matrix that occur in OA comes 
from the animal models. Initially there is an increase in water content in OA 
cartilage due to loss of elasticity of collagen network causing the hydrophilic 
proteoglycans to swell more than normally51. In early stage of OA the 
proteoglycan concentration may increase and the cartilage becomes thicker 
than normal and there is increased staining for proteoglycans51. At the same 
time water content also increases and the newly synthesized proteoglycans 
contain a higher proportion of chondroitin sulphate and lower proportion of 
keratan sulphate there by impairing the proteoglycan aggregation51. This 
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change in extracellular matrix occurs before fibrillation. As OA progresses 
ulcerations develop in the cartilage. Proteoglycan loss is accompanied by a 
decrease in ability to aggregate, persistence in abnormal glycosaminoglycan 
composition and also a decrease in chondroitin sulphate chain length. Once 
proteoglycan loss reaches a critical threshold level water content which initially 
increased falls below normal53. 
 
BIOMECHANICS AND DISEASE MECHANISMS OF 
OSTEOARTHRITIS 
Biomechanical changes 
 Two biomechanical theories of pathogenesis of OA suggest that 
mechanical stress injure chondrocytes, release the degrading enzymes, initiate 
the damage of the collagen network, ultimately causing the breakdown of the 
matrix. 
 
In OA cartilage the breakdown of the extracellular matrix leads to:   
- loss of elasticity and compressive stiffness resulting in greater mechanical 
stress on chondrocytes. 
- an increase in hydraulic permeability results in loss of interstitial fluid 
during compression and increase diffusion of solutes through the matrix. 
 
 Alterations in the inflammatory synovial fluid cause the disruption of 
normal fluid-film joint lubrication and loading dynamics54, 55. Joint friction, 
lubrication and contact mechanics are negatively affected by the loss of 
proteoglycans in the cartilage and superficial zone protein, LUBRICIN56, 57. 
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RESPONSE OF CARTILAGE TO MECHANICAL INJURY 
 Mechanical injuries often result in secondary OA58, 59. After injury, 
articular cartilage produces a repair tissue with neither the original structure nor 
the properties of normal cartilage. Chondrocytes in areas surrounding an 
injured zone are unable to regenerate repair tissue with similar structure, 
function and biomechanical properties of normal hyaline cartilage53. The lack 
of regenerative power in the articular cartilage is the most common finding. 
The regenerative fibrous tissue and fibrocartilage must have originated from 
the undifferentiated mesenchymal tissue arising from synovium, bone marrow 
and the superficial layer of articular cartilage60. 
 
 The reparative process of the avascular cartilage is not appreciated 
significantly, whereas the healing process in vascularized tissue, presents with 
three main phases viz., necrosis, inflammation and repair58, 61. In response to 
injury, cartilage undergoes initial phase of necrosis but cell death is minimal 
because chondrocytes are relatively insensitive to hypoxia58, 61. The 
inflammatory response is largely absent and the repair phase is limited due to 
vascularity. In lesions that do not cross tidemark, i.e., partial-thickness injuries, 
the burden of repair falls on chondrocytes – intrinsic repair61. Adult 
chondrocytes have little potential for replication and intrinsic repair. In lesions 
that cross the tidemark, extrinsic repair via differentiation and proliferation of 
mesenchymal stem cells occurs followed by a fibro cartilaginous regeneration. 
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The articular cartilage injury can be divided into three categories: 
1. micro-damage or repetitive trauma to the cells and matrix 
2. partial thickness or superficial injuries or chondral fractures that do not 
penetrate the sub-chondral plate 
3. osteochondral (full thickness or deep penetrating) injuries that extend 
through the tidemark and into the underlying subchondral bone58,61. 
 
 Trauma induces the release of proinflammatory factors (IL-1, TNF, 
Nitric oxide) and degrading enzymes which alter the material properties of the 
cartilage – cartilage matrix thins and subchondral bone stiffens accelerating the 
degenerative process53. 
 
 In lesions that do not cross the tidemark within 48-72 hours, the 
surviving chondrocytes increase the synthesis of extracellular matrix and type 
II collagen accompanied by cell proliferation and formation of clusters but this 
is transient and it falls back to normal level resulting in suboptimal repair53,61. 
Chondrocytes proliferating on the border of injured zone do not migrate into 
the defect and remain unfilled by the newly synthesized matrix53. 
 
 Lesions that cross the tidemark disrupt the underlying subchondral plate 
and elicit the three phase repair response like the vascularized tissues. Hence 
inflammatory process occurs and that stimulates a repair response. This helps 
in the process of fibro cartilaginous repair. The mesenchymal stem cells origin 
has been determined to be the underlying bone and they progressively 
differentiate into chondroblasts, chondrocytes, osteoblasts and synthesize 
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cartilage and bone matrices. After 6-8 weeks of injury, the repair tissue 
contains high proportion of chondrocyte like cells consisting of proteoglycans 
and type II collagen with less amount of type-I collagen whereas cells in the 
deeper layers of the defect differentiate into osteoblasts and undergo 
enchondral ossification to heal the subchondral bone defect. Finally there is a 
shift in the synthesis of collagen from type II to type I as the regenerative tissue 
undergoes a transformation to a more fibro cartilaginous repair. After one year 
of injury the repair tissue consists of a mixture of fibro cartilage and hyaline 
cartilage and 20-40% of type –I collagen62. Fibro cartilaginous repair is 
susceptible to early degenerative changes as it lacks the biomechanical 
properties to withstand normal physiologic joint loads62. 
 
MECHANISM OF TRANSDUCTION AND GENE EXPRESSION 
 Chondrocytes respond to mechanical stimuli via several regulatory 
pathways (e.g., transcription, translation, posttranslational modification, 
vesicular transport). In load-induced injury the superficial zone is more 
vulnerable than the middle and deep zones63. Normal stimuli help chondrocytes 
to maintain the extracellular matrix and abnormal stimuli disrupts this balance. 
 
 Mechanism of transduction influences the molecular structure of newly 
synthesized matrix molecules and the biomechanical tissue properties64. In 
chondrocytes cell matrix interactions via integrins are believed to be one of the 
important mediators in mechanotransduction. α5β1 integrin acts as 
mechanoreceptor in human articular chondrocytes. Mechanical stimulation 
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initiates a signal cascade which involves stretch-activated ion channels, actin 
cytoskeleton and focal adhesion complex molecules. This result in an anabolic 
response manifested by increased aggrecan and decreased MMP-3 expression. 
Mechanical stimulation activates Rho and Rho kinase pathways that are linked 
to the changes in the actin cytoskeleton65, 66. Stimulation of Rho/ROCK 
pathway is an anabolic stimulus which leads to nuclear translocation and 
activation of Sox9 – a “master regulator” of cartilage gene expression. Indian 
hedgehog (IHH) protein is a key signalling molecule which controls 
chondrocyte proliferation and differentiation. It also acts as an essential 
mediator of mechanism of transduction in cartilage: IHH protein expression by 
chondrocytes was shown to be induced by cyclic mechanical stress. 
 
 Integrins and integrin associated signalling pathways are partly 
regulated by mechanical stimulation which involves activation of plasma 
membrane apamin-sensitive calcium activated potassium channels resulting in 
membrane hyperpolarization after cyclic mechanical stimulation. Following 
mechanical stimulation in normal cartilage chondrocytes exhibit membrane 
hyperpolarization to cyclic pressure induced strain where as in OA cartilage 
chondrocytes exhibit membrane depolarization and no changes in aggrecan or 
MMP-3 messenger RNA67. The different signalling pathways responding to 
mechanical stimulation in healthy chondrocytes in comparison with OA, affects 
the disease outcome. 
 Fluid flow is sensed by chondrocytes in addition to cell and matrix 
deformation. A study using a tissue shear loading model suggested that 
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deformation of chondrocytes as well as the cells around the matrix, stimulated 
protein and proteoglycan synthesis68. 
 
ABNORMALITIES OF BONE 
Osteophyte Formation 
 Osteophytes are bony proliferations at the joint margins and in the floor 
of cartilage lesions that are responsible for the pain and restriction of joint 
movement in OA. Human osteophytes synthesize cartilage with significant 
amounts of type I collagen and nonaggregating proteoglycans69. Osteophytes 
are formed by penetration of blood vessels into the basal layers of degenerating 
cartilage or due to abnormal healing of stress fractures in subchondral 
trabeculae near the joint margins69. Subchondral cysts that occur in OA maybe 
created by entry of synovial fluid under pressure through defects in the 
cartilage or may occur in necrotic areas of the subchondral bone69. The 
increased venous pressure caused by the remodelled trabeculae and the cysts 
may contribute for some of the pain in OA. Glucocorticoids and 
immobilization have been shown to decrease the size and prevalence of 
osteophytes in OA of experimental models69. 
 
SUBCHONDRAL BONE SCLEROSIS 
 Early in OA increased remodelling and hardening of subchondral bone 
becomes evident even before the loss of cartilage thickness is evident 
radiologically70. The increased calcification results in the thinning of cartilage 
layer which increases the mechanical stress in adjacent areas of the cartilage. In 
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combination with subchondral bone sclerosis the altered mechanical 
environment and rapid bone remodelling may be contributing factors in 
cartilage degradation and OA pathogenesis. 
 
BONE MARROW LESIONS 
 Studies suggest that bone marrow lesions are associated with OA. They 
also contribute to the pain felt by OA patients. The study authors suggest that it 
“remains unclear whether bone marrow lesions precede, accompany or follow 
cartilage damage and volume loss in OA”71. Unlike cartilage, bone- marrow do 
not show a permanent structural change in OA. Several reports suggest that 
these lesions either resolve or regress but it is commonly observed that the 
bone marrow lesion scores increases over time72.  It has been postulated that 
oedema-like lesions are less severe and reversible whereas more advanced 
fibrotic and necrotic lesions are not73. There is a possibility that synovial fluid 
entering the subchondral bone marrow through intra-articular defects may alter 
the growth factor and cytokine environment that affects bone turnover. These 
findings suggest that there may be an altered biomechanical property of the 
subchondral tissues, which in turn would affect the biomechanical stress 
experienced by the adjacent cartilage. 
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ROLE OF INFLAMMATORY MEDIATORS IN DISEASE 
PROGRESSION 
 IL-1, IL-6, TNF and other classic inflammatory cytokines are elevated 
in the serum of patients with knee OA74. These cytokines auto-catalytically 
stimulate their own production, and thereby induce chondrocytes to produce 
chemokines, proteases, eicosanoids (prostaglandins and leukotrienes) and nitric 
oxide. Within cartilage the action of these inflammatory mediators is 
predominantly to activate catabolic pathways, promote cellular apoptosis and 
inhibit matrix synthesis. Though OA is not considered as an inflammatory 
response, “inflammatory” mediators from the affected tissues perpetuate 
disease progression and hence may represent potential targets for disease 
modification. Inflammatory molecules that are produced by articular cartilage 
include cytokines, chemokines, proteinases, nitric oxide, TGF-β, hyaluronic 
acid, prostaglandins, F-spondin. 
 
NITRIC OXIDE 
 The chondrocytes in response to pro-inflammatory cytokines produce a 
major catabolic factor – Nitric oxide, produced by inducible isoform of nitric 
oxide synthase (iNOS) . Evidence suggests that the over production of nitric 
oxide by chondrocytes plays an important role in the perpetuation of cartilage 
destruction in OA. Without stimulation by cytokines the normal cartilage 
usually do not produce nitric oxide or express iNOS, but in OA cartilage they 
spontaneously produce large amounts of nitric oxide. iNOS is also upregulated 
from chondrocytes by cartilage compression75,76. 
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 The multiple effects exerted by nitric oxide on the chondrocytes to 
promote the articular cartilage degradation include the following. 
1. Inhibition of synthesis of collagen and proteoglycan  
2. Activation of the metalloproteinases 
3. Increase in susceptibility to injury by other oxidants 
4. Apoptosis 
 
F-SPONDIN 
 F-spondin is a neuronal extracellular matrix glycoprotein that appears to 
regulate cartilage degradation through the TGF-β and PGE2 pathways. One of 
the recent articles suggests that addition of F-spondin in vitro to OA cartilage 
tissue led to increased levels of production of PGE2 as well as accelerated 
collagen degradation and reduced proteoglycan synthesis both of which are 
dependent on these two molecules77. 
 
ALTERATIONS IN BONE 
 Nitric oxide seems to have a role in OA as it contributes to the alteration 
in the subchondral bone. The endothelial cell nitric oxide synthase (ecNOS), 
endothelial isoform expressed in bone, seems to play a key role in regulating 
osteoblast activity and bone formation. Along with prostaglandins, ecNOS 
promote bone formation and suppress bone resorption. In bone cells IL-1 and 
TNF induce iNOS to produce nitric oxide which then potentiates the bone loss. 
Anabolic growth factors like IGF-1 and TGF-β are highly expressed in 
osteophytes in OA patients. Areas of “hot spots” increased radionuclide uptake 
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on bone scintigraphy identify OA joints that are more likely to progress by 
radiographic criteria and/or to require surgical intervention over a 5 year 
period. 
 
ALTERATIONS IN SYNOVIAL TISSUE 
 Synovial effusion and synovial lining inflammation have emerged as 
another key feature of OA pathophysiology. The localized inflammation of the 
synovium suggests that localized proliferation and inflammatory changes in the 
synovium occur in up to 50% of patients with OA. The activated synovium 
produce proteases and cytokines accelerating the damage to adjacent cartilage. 
 
 The clinical symptoms and signs in OA reflect synovial inflammation in 
the joints. The histologic changes in the synovium include hypertrophy and 
hyperplasia with an increase in the number of lining cells along with scattered 
foci of lymphocytes in the sub lining tissue. The synovial inflammation in OA 
is confined to areas adjacent to pathologically damaged cartilage and bone. 
These activated synovium release proteinases and cytokines, accelerating the 
destruction of adjacent cartilage. 
 
 Metalloproteinases that degrade the cartilage are produced not only by 
the cartilage but also by the synovium. The mechanical or enzymatic 
destruction of cartilage enhance the release of cartilage breakdown products 
from the articular surface and provoke the release of collagenase and other 
hydrolytic enzymes from synovial cells and macrophages. The cartilage 
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breakdown products is thought to result in vascular hyperplasia and 
mononuclear cell infiltration in the synovial membrane in OA. 
 
 Recent studies of arthroscopic specimens of patients with early OA 
revealed that synovial tissues  in early OA had higher levels of IL-1β ,TNF and 
increased mononuclear cell infiltration when compared with late OA78 , that are 
likely to be the contributors to the degradation cascade. Reports suggest that 
there is an increase in the number of immune cells in the synovial tissue, 
including B cells and activated T lymphocytes. Evidence suggests that patients 
with OA express cellular immunity to the C1 domain and cartilage 
proteoglycan link protein. Figure-2 
 
 
 
  
  
 
 
 
FIGURE-2- FACTORS PREDISPOSING TO OSTEOARTHRITIS 
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CLINICAL FEATURES 
 The joints commonly affected by OA include knee, hand, hip and spine; 
may be symptomatic or asymptomatic with only radiological change. Patients 
with OA describe pain in the joint that is worse with activity, with limited 
morning stiffness (<30min), pain and stiffness with rest. In OA in affected 
joints there is often bony enlargement and crepitus on examination and 
concomitant reduction in range of motion. Complaints of pain may be more or 
less than the expected on the basis of structural damage79, 80.  
SYMPTOMS AND SIGNS IN  KNEE OA: 
SYMPTOMS:  
1. Pain – Knee OA is characterized by the insidious onset of pain with 
limited range of motion. They frequently describe pain and limitation 
with walking, transferring as from seated to standing, especially stair 
climbing. They are associated with a sensation of instability or “giving 
out” at the knee. 
2. Stiffness – Due to stiffness, loose bodies in the joint space or meniscal 
lesions, there is a “locking” sensation at the knee joint. 
3. Effusions – Effusions are usually non inflammatory that is without 
redness. Sometimes when large they are associated with popliteal bursa 
enlargement (Baker’s cyst). In knee OA pain over the anserine bursa or 
greater trochanter may be related to altered biomechanics81. 
4. Deformity and loss of function – The most common mal-alignment 
that is often seen in severe disease is the varus deformity which may act 
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as a risk factor for progression82. Deformity may result from capsular 
contracture or joint instability. Difficulty in climbing stairs and 
restriction of walking distance eventually makes the patient to seek 
medical help. 
SIGNS  
1. Joint swelling – May be the first sign due to an effusion. Scars suggest 
previous abnormalities and muscle wasting denotes longstanding 
dysfunction. 
2. Deformity - The most common deformity in knee – varus deformity. 
3. Local Tenderness – Pain may be elicited by palpation of the medial or 
lateral joint line or both. 
4. Crepitus – Patients with knee OA often have crepitus during passive 
movements and bony enlargement. 
5. Other signs – include flexion deformities or joint instability. 
              In women an early modifiable risk factor for knee progression is 
quadriceps weakness83,84 and in late stages there may be apparent muscle 
atrophy85,86. Alterations in proprioception and vibratory sense have been found 
to be associated with knee OA, although the relation of these factors to pain 
and progression is still unclear87,88.  
              The most important cause that is often overlooked is patella-femoral 
OA that can strongly contribute to pain and disability at the knee. Patella-
femoral joint OA is often located anteriorly and is characterized by pain with 
ascending or descending stairs. It can also be associated with tibio-femoral OA. 
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DIAGNOSTIC TESTING 
              OA is mostly diagnosed clinically, rarely laboratory testing is used. 
The purpose of additional diagnostic testing is to exclude the potentially 
treatable underlying conditions such as metabolic or inflammatory 
arthropathies. Before initiation of pharmacologic therapy in OA complete 
blood count, glucose, creatinine, and liver function tests should be obtained. 
Evaluation for hypothyroidism and hemochromatosis may be required in cases 
where there is prominent involvement of the metacarpophalangeal joints. 
 
SYNOVIAL FLUID  
               The synovial fluid in OA is normal or mildly inflammatory, appearing 
clear/ colourless to slightly yellowish. The leukocyte cell count is less than or 
equal to 2000 cells/cu.mm that is less than 2cells across 10 high-power fields89. 
In case of effusion diagnostic aspiration may be done. 
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IMAGING: Conventional Radiography  
General Considerations 
                  Conventional radiography is a relatively inexpensive easily 
available technique useful to confirm the diagnosis and exclude other causes, 
when there is clinical uncertainty regarding the diagnosis. Joint space 
narrowing, sclerosis, osteophytes and cysts of subchondral bone90 are seen in 
radiographs of joints affected by OA. 
                 Imaging of the knees should be bilateral and in weight bearing 
(standing position) and should generally be antero-posterior (AP) for clinical 
purposes. The Kellgren-Lawrence (K/L) grading system remains the most 
commonly used one for research purposes91. KL grades range from 0 to 4 and a 
grade of 2 is generally considered diagnostic of OA. 
 
KELLGREN AND LAWRENCE CLASSIFICATION 
Grade 1: Doubtful narrowing of joint space and possible osteophytic lipping 
Grade 2: Definite osteophytes and possible narrowing of joint space 
Grade 3: Definite narrowing of joint space, moderate multiple osteophytes, 
some sclerosis and possible deformity of bone contour 
Grade 4: Marked narrowing of joint space, large osteophytes, severe sclerosis 
and definite deformity of bone contour - joint displacement. 
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 IMAGING: Advanced Modalities   
                          MRI is now being increasingly used in OA research as a means 
to   obtain information about structural changes earlier in the disease process 
before findings are apparent on conventional radiographs. Bone marrow lesions 
identified on knee MRI have been shown to correlate with pain, meniscal 
lesions, bone attrition and progressive cartilage damage92. Ultrasound may 
have a role at the bedside in detecting small effusions, identifying early 
cartilage changes, differentiating inflammatory from non-inflammatory 
arthropathies and as a therapeutic adjunct to allow more accurate aspirations 
and placement of intra-articular injections93. 
 
BIOMARKER OF OSTEOARTHRITIS 
The targets fixed in a biomarker research in OA include the following. 
1. Early detection before irreversible damage occurs 
2. Predicting OA progression 
3. Monitoring response to therapeutic intervention 
 
 The OA Biomarkers Network funded by the National Institute of Health 
established the “BIPED” biomarker classification with five separate categories 
of surrogate markers: burden of disease, investigative, prognostic, efficacy of 
intervention and diagnostic94. 
 
 The burden of disease and prognosis for hip and knee OA biomarkers 
are serum COMP, serum hyaluronic acid and urinary CTXII94. 
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            The major structural components that are unique to cartilage are type II 
collagen and aggrecan. The proteins COMP, cartilage link protein, matrilin, 
minor collagens (types I, V, VI, IX, & XI), cartilage intermediate layer protein 
(CILP) and hyaluronic acid are other additional constituents of articular 
cartilage. In normal healthy cartilage there is relatively a slow turnover rate of 
these molecules but in OA it is characterized by enhanced synthesis and 
enzymatic degradation of most of these molecules. Therefore recently much 
focus has been on detecting biomarkers of cartilage matrix synthesis and 
degradation in OA94. In addition to markers of turnover and matrix 
degradation, recent advances in the proteomics and microRNA have enabled 
detection of new OA biomarkers using screening of serum constituents in 
arthritis patients95. The slow progression of primary OA is causing the 
researchers to refocus the search for OA biomarkers on secondary OA which is 
more rapidly progressing after acute injury96. 
 
 The researchers suggested that a single measurement of serum 
hyaluronic acid or short term increases in urine CTXII would identify patients 
at greatest risk for progression of OA97. Inflammatory markers such as CRP are 
moderately but significantly increased in early knee OA and can be predictive 
of OA that will progress over time94. 
 
 COMP, a non-collagenous extracellular matrix protein is synthesized 
both by cartilage and synovium along with TGF-β, stimulation being in 
articular cartilage. Studies show that in knee OA serum levels of COMP are 
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often higher with more rapidly progressive joint damage98. COMP is one of the 
useful serum marker of OA, lacking specificity and have high variations in 
serum which necessitates the use of additional markers, for correlation. The 
development of specific reagents to detect degradation products of COMP may 
increase its utility as an OA biomarker99. Serum COMP levels indicate a 
specific stage of OA. 
 
OSTEOPONTIN  
                                        Structure of osteopontin 
 
              OSTEOPONTIN (OPN) – a recently discovered ubiquitous 
glycoprotein, secreted by various cells of the body has been found to 
mineralize the bone matrix by anchoring to bone cells. OPN plays an important 
role in migration of neutrophil and degranulation of the mast cells. OPN is one 
of the newly emerging biomarker with diverse physiological role in our body. 
OPN is found both in body fluids as well as extracellular matrix. OPN is an 
acidic, phosphorylated sialic acid rich calcium binding glycoprotein with 314 
amino acids. OPN was first identified by Oldberg et al100 in 1986 in the 
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osteoblast cell. The human gene mapped for the osteopontin is on 
chromosome4q. The receptor protein contains an Arg-Gly-Asp sequence which 
acts as a cell adhesion sequence and recognises various integrins101. OPN is 
synthesized in fibroblasts102, pro-osteoblasts, osteoblasts or osteoclastic cell in 
bone and found in kidney, specialized epithelial tissues like uterine epithelial 
cell, smooth muscle cell103, skeletal muscle myoblasts104, dentritic cells and 
macrophages105. OPN, a member of the “small integrin-binding ligand N-
linked glycoprotein (SIBLING) family” is known as “early T cell activation-1 
protein (Eta-1)”. 
 
 Experimental evidence suggests that hypocalcemia and 
hypophosphatemia lead to an increase in OPN transcription, translation and 
secretion106 by stimulating the proximal tubule of the kidney to produce 
calcitriol, due to the presence of vitamin-D response element (VDRE), in the 
OPN gene promoter. It has been identified that extracellular inorganic 
phosphate is one other modulator of OPN expression107. 
 
Bone remodelling 
 The important role of OPN in bone is anchoring the osteoclasts to the 
bone mineral matrix108. The organic constituents like type I collagen, 
osteonectin, osteocalcin, alkaline phosphatase and OPN constitute about 20% 
of the dry weight of the bone. 
 
 OPN is considered essential for the initiation of the process by which 
osteoclasts can develop ruffled borders for bone resorption9. It is a product of 
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cells present in the osteoid matrix and forms a bridge (Latin-Pons) between 
cells and the mineral in the matrix100 and hence was named as 
“OSTEOPONTIN”. 
 
Renal stone formation  
 In humans the primary composition of urinary stones are calcium salts. 
Most individuals do not form stones even though normal urine is 
supersaturated with calcium oxalate. This suggests that there are some factors 
that inhibit urinary stone formation. UROPONTIN, the urinary form of OPN 
has been shown to reduce growth109 and aggregation110 of calcium oxalate 
crystals .They block the binding of the crystals to the renal epithelial cells111. 
             Calcium oxalate monohydrate (COM) growth and aggregation is 
inhibited by UROPONTIN. OPN in addition favours the formation of calcium 
oxalate dehydrate (COD) which is less adherent to the renal epithelial cells than 
COM112. 
Immune function 
              Thrombin cleavage modifies the full length OPN (OPN-FL) and this 
exposes the non-cryptic sequence SVVYGLR on the cleaved form of protein 
known as OPN-R. The cleaved OPN exposes epitope for the integrin receptors 
of α4β, α9β4 and α9β1113. These integrin receptors are present in immune cells 
such as mast cells108, neutrophils114 and T cells. These are also expressed by 
macrophages and monocytes115. 
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             OPN is reported to act as an immune modulator in various ways: 
1. The chemotactic property of OPN helps in promoting cell 
recruitment to inflammatory sites 
2. Acts as an adhesion protein and help in cell attachment and wound 
healing 
3. OPN mediates cell activation and cytokine production 
4. Regulation of apoptosis by promoting cell survival 
 
 OPN is important for neutrophil migration in vitro and plays a role in 
migration/degranulation of mast cell116, profoundly a macrophage chemotactic 
factor117. (Figure-3) 
  
 
 
 
 
 
FIGURE-3- IMMUNOLOGICAL FUNCTIONS OF OPN 
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Cell activation 
              OPN inhibits production of T “helper”-2 cytokine IL-10, enhancing T 
“helper”-1 response. OPN influences cell mediated immunity and enhances B 
cell immunoglobulin production and proliferation101. 
 
Apoptosis 
             In many circumstances OPN acts as an important anti-apoptotic factor. 
On exposure to harmful stimuli OPN blocks the activation induced cell death of 
macrophage and T cells as well as fibroblasts and endothelial cells118, 119. In 
inflammatory colitis OPN prevents non programmed cell death120. 
 
Role in vascular smooth muscle cell (VSMC) remodelling 
            OPN is a matrix molecule whose expression is increased dramatically 
by angiotensin II. OPN has been shown to exert an important effect on VSMC 
growth121. OPN induces both  formation of new intima after injury and medial 
thickening without injury suggesting that it plays a role in development of 
vascular remodelling after angioplasty in vivo. OPN is one of the most highly 
induced proteins at sites of epithelial injury. In atherosclerotic lesions OPN 
appears to promote early inflammatory mechanism associated with macrophage 
recruitment122. 
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OSTEOPONTIN: A CULPRIT PROTEIN IN OSTEOARTHRITIS  
              OPN is considered as a pro inflammatory cytokine. Its altered 
expression may be involved in pathological conditions viz., inflammatory 
disease, autoimmune disease, osteoporosis, joint diseases and cancer 
metastasis123. 
 
             OPN is considered as a critical intrinsic regulator that plays an 
important role in progression of OA. OPN expression has been shown to be 
increased in the joints of the patients and it has been reported to be correlated 
with the severity of inflammatory status and joint lesion in OA patients124-126. 
Honsawek et al101 analysed OPN levels in both synovial fluid and plasma of 
patients with OA and healthy subjects and found significantly higher OPN 
levels in both synovial fluid as well as  in plasma of patients with  knee OA 
when compared to healthy subjects. Similarly Mohammed et al127 has analysed 
OPN levels in both synovial fluid/ plasma of patients with OA and healthy 
subjects. Significantly higher OPN levels in both synovial fluid as well as  in 
plasma of patients with knee OA was seen,  when compared to healthy 
subjects. According to these studies the increased level of OPN was suggested 
to be related with the progressive damage of the joint in OA. Gao et al125 
investigated OPN levels in both articular cartilage and synovial fluid to 
evaluate the possible correlation with the radiological grading and Mankin 
score (histo -pathological tool to classify the severity of OA lesions of 
cartilage). They found higher OPN concentration in articular cartilage and 
synovial fluid when compared to healthy subjects. Qin et al128 analysed 
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synovial fluid OPN in patients with OA and higher OPN mRNA and protein 
expression was observed and they found it to be closely related to the 
development of OA. Xu et al129analysed the phosphorylation level of OPN in 
OA cartilage by immuno-precipitation technique. They found a higher 
phosphorylation level of OPN in OA cartilage when compared to normal 
cartilage. They suggested that OPN phosphorylation might be related to the 
cartilage degeneration. Pullig et al130 analysed the expression of OPN level in 
OA cartilage in humans and found an increased OPN protein deposition and 
mRNA expression in deep zone of articular cartilage of patients with OA. 
Martinez-Calleja et al131 found that in the early stages of OA in the superficial 
zone of the articular cartilage there was an increased expression of OPN. Zhang 
et al. found that in OA patients there was an increased level of OPN in 
fibroblast-like synoviocytes (FLS). In patients with OA they also investigated 
the effect of HA on the expression of OPN mRNA of FLS and found that the 
high expression of OPN mRNA is a consequence of increased HA level in OA 
synovitis. Mat sui et al132 generated OPN deficient mice and found that OPN 
deficiency was associated with more severe OA as OPN might be required for 
cartilage homeostasis and to prevent OA progression. Thus, these studies 
suggest that the abnormal level of OPN in synovial fluid, plasma, or articular 
cartilage might be related to OA and hence OPN can serve as a valuable 
diagnostic biomarker for determining the disease severity. 
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ROLE OF OSTEOPONTIN IN PATHOGENESIS OF 
OSTEOARTHRITIS 
 The increased OPN expression is involved in the molecular 
pathogenesis of OA, the pathological mechanism being obscure. The main 
pathological change in OA is the degeneration of articular cartilage133. 
Appropriate joint load stimulates the chondrocytes to maintain the cartilage 
homeostasis. In chondrocytes abnormal mechanical load alters the composition 
and metabolism of articular cartilage which then induce the release of OPN and 
this enhanced level of OPN in cartilage led to the induction of MMP-13129. 
This MMP-13 is thought to be involved in the degradation of cartilage matrix 
components type II collagen and proteoglycan release from cartilage tissues. 
The loss of proteoglycan and excessive cleavage of type II collagen facilitated 
the development of OA132. The elevated levels of OPN in cartilage tissue 
activate the transcription factor NF-κ B pathway which is involved in the 
production of many inflammatory factors like chemokines and cytokines (IL-1, 
IL-6, IL-8, CCL2, CXCL1etc) in cartilage that leads to the spontaneous 
production of these cytokines as well as mediators and exert injurious effects 
on function of chondrocytes that leads to an imbalance of cartilage homeostasis 
which results in progressive articular degeneration125.Fig-4. 
  
  
 
FIGURE-4- ROLE OF OPN IN OA PROGRESSION 
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DIAGNOSTIC ASPECTS OF OSTEOPONTIN IN OSTEOARTHRITIS 
  OA, the most common form of arthritis characterized by progressive 
degeneration of articular cartilage is one of the leading causes of morbidity in 
the aging population134. In the recent times, though the early diagnosis of OA 
has gained attention with improvement in the prognosis with the conventional 
therapy, the treatment of OA still remains unsatisfactory. Hence to develop 
innovative therapeutic strategies, a greater understanding of the pathogenic 
mechanism of OA becomes essential.  For effective prevention and therapeutic 
treatment of OA, the need for identification of appropriate mediators of joint 
destruction is required135. OPN can serve as a promising biomarker for 
diagnosis of OA as high level of OPN is frequently found in the synovial fluid 
and plasma of OA patients. 
 
 Singh et al136 in a recent study proposed stem cells as a therapeutic 
choice for cartilage repair in OA patients. The use of biochemical markers has 
recently been proposed to:  
 
i. diagnose the disease at an earlier stage  
ii.  assess the severity of the disease   
iii. to develop a safe and effective disease modifying treatment for OA 
patients137. 
 
Hence OPN may serve as a useful diagnostic biomarker for the treatment 
and prognosis of OA123. 
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THERAPEUTIC ASPECTS OF OSTEOPONTIN IN 
OSTEOARTHRITIS 
Therapeutic research on OA may involve two main strategies as follows. 
1. To elucidate the mechanism of joint pain 
2. The mechanism of articular cartilage degradation124. 
 
 Yumoto et al138, in his study to investigate the role of OPN in the 
pathogenesis of inflammatory process induced a mixture of anti-type II 
collagen mAbs and lipo polysaccharide (mAbs-LPS) in an arthritis model.  
They found that OPN deficiency prevents the model mice from loss of 
proteoglycan in the articular cartilage, swelling and destruction of joints via 
promotion of angiogenesis and induction of apoptosis in chondrocytes. 
Yamamoto et al139 in the murine arthritis model investigated the effect of an 
anti-OPN antibody (M5Ab) by inducing a mixture of four anti-type II collagen 
monoclonal antibodies. They found that M5Ab significantly inhibited the 
cartilage degeneration and suppressed the development of arthritis in their 
murine study model139. Yamamoto et al investigated the effect of C2K1 in 
CYNOMOLGUS MONKEY by constructing a chimeric anti-OPN antibody 
and they found that C2K1 prevents the destruction of bone and cartilage in the 
joints of this collagen induced arthritis in non-human primates significantly. 
 
 Fan et al140 in his study reported that anti-OPN mAb, 23C3 reduces the 
levels of serum type II collagen specific autoantibodies and pro inflammatory 
cytokines and suppressed T cell recall responses to type II collagen and inhibits 
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the development of collagen induced arthritis in DBA/1J mice immunized with 
type II collagen to induce collagen induced arthritis140. 
 
 Due to lack of enough evidence more investigations are necessary to 
define the signalling events induced by OPN for the inhibition of OPN 
mediated inflammatory process, because targeting these signalling events and 
reducing the expression of OPN, may be successful in the treatment of OA. 
 
HYALURONIC ACID 
 Hyaluronic acid (HA) is an anionic, non-sulphated glycosaminoglycan 
present in connective tissue, neural and epithelial tissues. This high molecular 
weight glycosaminoglycan is formed in the plasma membrane and is one of the 
chief components of ECM and contributes to cell proliferation and migration as 
seen in progression of some malignant tumours144, 145. The average 70 kg man 
has 15gms of hyaluronic acid in the body, one-third of which is synthesized 
and degraded daily146. 
 
Structure 
Structure of Hyaluronic acid 
 
                 In the 1930s Karl Meyer first determined the properties of 
hyaluronic acid147. Hyaluronic acid is a polymer of disaccharides composed of 
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D-N-acetyl glucosamine and D- glucuronic acid linked by alternating β-1,4 and 
β-1,3 glycosidic bonds. In human synovial fluid, the average molecular weight 
of hyaluronic acid is 3-4 million Da and polymers can range in size from 5000-
20,000,000 Da in vivo. Hyaluronic acid can be 25,000 disaccharide repeats in 
length. 
 
Synthesis 
 HA is synthesized by a class of integral proteins namely hyaluronan 
synthase of three types  - HAS1, HAS2, HAS3. These enzymes lengthen HA 
by adding N-acetyl glucosamine and glucuronic acid repeatedly to the nascent 
polysaccharide as it is extruded via ABC transporter through the cell membrane 
into the extracellular space148. 
 
 HA synthesis has been shown to be inhibited by a 7-hydroxy 4-methyl 
coumarin derivative which is 4-methyl umbelliferone149. This selective 
inhibition is helpful in preventing the metastasis by tumour cells150. When 
tested in cultured human synovial fibroblasts, there is a feedback inhibition of 
HA synthesis by low molecular weight HA (<500kDa) at high concentrations 
and stimulation by high molecular weight HA (>500kDa) 151. 
 
Functions 
 Until late 1970s HA was thought to be a major component of the 
synovial fluid which increased the viscosity of the fluid and had lubricating 
function along with lubricin. HA is an important component of articular 
cartilage which coats around each chondrocyte. Aggrecan monomers bind to 
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hyaluronan in the presence of hyaluronan and proteoglycan link protein 1 
(HAPLN1) forming large negatively charged aggregates that imbibe water 
contributing to the resilience of the cartilage. The amount of HA in cartilage 
increases but the molecular weight of HA decreases with age152. 
 
 HA is a major component of skin and is involved in tissue repair. HA 
degradation products accumulate in the skin after UV exposure because the 
cells in the dermis stop producing HA thereby increasing its rate of 
degradation153. 
 
 HA contributes to proliferation and migration of cells. It participates in a 
number of cell surface receptor interactions. Its contribution to tumour growth 
is due to its interaction with CD44 which is required for cell adhesion 
interactions of tumour cells. 
 
Degradation 
 HA is degraded by hyaluronidases. In humans, there are seven types, 
most of which are tumour suppressors. HA on degradation forms 
oligosaccharides and very low molecular weight HA which exhibit pro-
angiogenic properties154 and they can also induce inflammatory responses in 
macrophages and dendritic cells in tissue injury155, 156. 
 
Cell receptors for HA 
 Cell receptors for HA fall into three groups- CD44, receptor for HA 
mediated motility (RHAMM) and intercellular adhesion molecule-1(ICAM-1). 
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 The binding of HA-CD44 was first demonstrated by Aruffo et al157 in 
1990 and till date it is recognized as the main cell surface receptor for HA. This 
binding plays an important role in the various physiologic events viz., cell 
migration, proliferation, activation, cell-cell and cell-substrate adhesion, 
endocytosis of HA leading to its catabolism in macrophages and assembly of 
peri-cellular matrices from HA and proteoglycan158, 159. 
 
 ICAM-1 is a metabolic cell surface receptor for HA and is responsible 
mainly for the clearance of HA from lymph and blood plasma158, 160. Ligand 
binding of this receptor triggers a highly co-ordinated cascade of events that 
include the formation of endocytic vesicle and its fusion with primary 
lysosomes which causes enzymatic digestion to monosaccharides which are 
transported to cell sap, phosphorylation of GlcNac and enzymatic 
deacetylation158,161,162. The binding of HA to ICAM-1 mediated inflammatory 
activation.159 
 
CLINICAL SIGNIFICANCE 
 HA levels correlate well with malignancy. Hence it is often used as a 
tumour marker (prostate and breast cancer), and to monitor the prognosis of the 
disease163, 164. 
 
Wound repair and inflammation 
 In the early inflammatory phase of wound repair there is abundant HA 
in wound tissue due to increased synthesis159. HA acts as a promoter of early 
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inflammation and acts as a moderator of inflammatory response and helps in 
stabilization of granulation tissue matrix. HA can protect against free radical 
damage in cells165. HA functions in the negative feedback loop of inflammatory 
activation159. TNF-α stimulates the expression of TSG-6(TNF-stimulated gene 
6), a HA binding protein which forms a stable complex with serum proteinase 
inhibitor IαI (Inter-α-inhibitor) with a synergistic effect on latters plasmin 
inhibitory activity. Plasmin is involved in the activation of proteolysis cascade 
of matrix metalloproteinases and other proteinases causing inflammatory tissue 
damage. Hence the action of TSG-6/IαI complex may additionally get 
organised by binding to HA in the ECM and may serve as a potent negative 
feedback loop to inflammation and stabilize the granulation tissue as healing 
progresses159, 166. 
 
Granulation and organization of the granulation tissue matrix 
 HA is abundant in the granulation tissue matrix and are essential for 
tissue repair. HA helps in cell migration, proliferation, and organization of 
granulation tissue matrix159. HA is synthesized in the plasma membrane and 
released directly into the extracellular environment, contributing to the 
hydrated microenvironment at the sites of synthesis.  In the basal layer of the 
epidermis where proliferating keratinocytes are found there is a relative high 
concentration of HA in normal skin167. The main functions of HA in epidermis 
are maintaining the extracellular space and providing an open, well hydrated 
structure for the passage of nutrients. 
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Foetal wound healing and scarring 
 HA content in foetal wounds is higher than in adults suggesting that HA 
atleast in part may reduce collagen deposition and hence may lead to reduced168 
scarring. 
 
HYALURONIC ACID IN OSTEOARTHRITIS 
 Even though majority of circulating HA originates from extra 
cartilaginous sources, it is considered as a marker of cartilage degradation 
which can be detected in the serum and synovial fluid98. The proteoglycan 
reflects cartilage turnover whereas HA reflects synovial activity98. In 
addition, higher serum HA levels have been correlated with the number of 
joints involved and degree of clinical disability. These findings support the 
theory that serum HA levels reflect synovial hyperactivity. Hence serum HA 
levels may serve as a predictor of OA disease progression98 to be correlated 
with the radiological evidence of disease progression over a five year interval, 
as patients with advanced disease had higher levels of HA than at the outset98. 
 
 HA is produced locally by cells of the ECM. In addition to its structural 
properties it is thought to play a role in cell signalling. The release of HA/HA 
fragments into the systemic circulation is due to degradation and turnover of 
the ECM from arthritic joints. After entering the systemic circulation they are 
cleared by the liver as well as the lymphatics via a HA-specific receptor after 
endocytosis141. Increased production and release of HA are thought to reflect 
the localized inflammation occurring in the synovial lining and the cartilage 
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degradation142. The joint stiffness and oedema in arthritis is due to increased 
HA in inflamed synovium143. 
 
 Accordingly in this case control study, the concentrations of plasma 
OPN and serum HA in patients with knee OA  was assessed at Rajiv Gandhi 
Government General Hospital to evaluate the diagnostic value of plasma OPN 
and serum HA in patients with knee OA. 
  
Aims & objectives 
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AIMS & OBECTIVES 
 
AIMS:  
1. To evaluate, if plasma osteopontin can be used as a biomarker to 
monitor the severity of knee osteoarthritis.  
2. To assess the role of osteopontin in the pathogenesis of  osteoarthritis by 
stimulating MMP13, thereby increasing hyaluronic acid levels in serum.   
 
OBJECTIVES:  
1. To correlate plasma osteopontin level with radiological grade in patients 
with knee osteoarthritis. 
2. To correlate plasma osteopontin level with serum hyaluronic acid in 
patients with knee osteoarthritis. 
 
  
Materials & methods 
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MATERIALS AND METHODS 
 
 The present study - “Correlation of plasma osteopontin with radiological 
grading in patients with osteoarthritis in the knee joint”, is a case control study 
carried out during the period between January 2015 to June 2015 at Madras 
Medical College and Rajiv Gandhi Government General Hospital. This study 
was conducted after obtaining INSTITUTIONAL ETHICS COMMITTEE 
clearance. 
 
Population of the study 
Inclusion criteria for cases 
 The study group comprised of 60 cases of osteoarthritis patients, 
comprising of 48 adult females and 12 adult males. Patients with signs and 
symptoms as well as radiologic evidence of OA were selected. Patients were on 
treatment with NSAIDs and calcium supplements. The inclusion criteria for 
cases include: 
1. Unilateral or bilateral knee osteoarthritis 
2. Duration of  knee pain > three months 
3. Age 40-70 yrs 
4. Radiological evidence of osteoarthritis  
 
Inclusion criteria of control 
 The control group comprised of 30 adults, age and gender matched 
individuals, with 23 females and 7 males. They had no symptoms and signs of 
OA and their X-ray knee joint was normal- no evidence of OA. 
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Exclusion Criteria  
1. Patients with secondary osteoarthritis-post-traumatic or post 
inflammatory 
2. Renal failure & hepatic failure patients 
3. Generalised osteoarthritis 
4. Patients with both hip and knee osteoarthritis 
5. Patients with malignancy 
 
Sample collection and storage 
 After obtaining informed consent from the patients attending the Out-
Patient Department, Institute of Orthopaedics, Rajiv Gandhi Government 
General Hospital, Chennai, blood samples were collected. 
 
 5mL of blood was collected from the ante-cubital vein of the study 
population- both cases and controls (60,30 respectively). The blood was 
aliquoted in to three tubes. One tube containing EDTA as anticoagulant and 
2mL of blood was transferred up to the prescribed mark on the tube. The tube 
was gently shaken between the palms for uniform mixing. In another red 
capped serum tube another 2mL of blood was transferred. The remaining 1mL 
of the blood was transferred in to a plain tube for the further processing of the 
sample. 
 
 The sample tubes were labelled and stored in ice box during their 
transport to the biochemistry laboratory. The samples were centrifuged within 
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45 minutes of collection and plasma/serum from each tube was aliquoted   into 
a separate sample storage eppendorf tubes. Samples were stored in deep freezer 
at-20oC until further processing. Plasma samples were used for osteopontin 
estimation and serum samples were used to estimate hyaluronic acid, 
calcium and phosphorus. 
 
ESTIMATION OF PLASMA OSTEOPONTIN 
 Plasma osteopontin level was estimated using the Sandwich Enzyme 
Linked Immuno Sorbent Assay (ELISA) method (Ray Biotech). The kit was 
stored at 2-8oC in a refrigerator.  
 
Principle  
 Quantitative ELISA using sandwich technique was performed to analyse 
OPN concentration in the plasma of both cases and controls. The micro-plate 
provided was already coated with an antibody specific for human OPN. The 
standards and samples were then pipetted into the wells and the OPN present in 
the sample were bound to the wells by the immobilized antibody. The wells 
were then washed and biotinylated anti-human OPN antibody was added. After 
washing away unbound biotinylated antibody, HRP-conjugated streptavidin 
was pipetted in to the wells. The wells were then again washed, and a 
TETRAMETHYLBENZIDINE (TMB) substrate solution was added to the 
wells and colour developed in proportion to the amount of OPN bound. The 
stop solution was then added and the colour changed from blue to yellow, and 
the intensity of the colour was then measured at 450 nm. 
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Reagents 
1. OPN micro plate: 96 wells (12 strips x 8 wells) coated with anti-human 
OPN. 
2. 25 mL of 20 x wash concentrate solution. 
3. 2 vials of recombinant human OPN standards. 
4. 30 mL of animal serum with 0.09% sodium azide as preservative (Assay 
Diluent A) was used as standard and sample diluent for serum and 
plasma samples. 
5. 15 mL of 5x concentrated buffer (Assay Diluent B) can be used as 
standard and sample diluent for culture and urine samples. 
6. Biotinylated anti-human OPN vials were used as detection antibody 
OPN. 
7. 200 μL of 500 x concentrated HRP-conjugated streptavidin (HRP-
Streptavidin Concentrate). 
8. 12 mL of 3,3’,5,5’- tetramethylbenzidine (TMB) in buffered solution 
was used as one step TMB substrate solution. 
9. 8 mL of 0.2 M sulfuric acid was used as stop solution. 
 
Preparation of reagents and standards: 
 All reagents and samples were brought to room temperature (18 - 25°C) 
before use. 
1. Sample dilution:  Samples were diluted (1in100 dilution) with Assay 
Diluent A.  
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2. Assay Diluent B was diluted to 5-fold with deionized water.  
3. Standard preparation: First the vial containing standard was given a brief 
spin before preparing various concentrations of the standard and for 
plasma samples 400 μL Assay Diluent A was added into standard vial to 
prepare a 100 ng/mL standard. Then the powder was dissolved 
thoroughly by a gentle mix. 90 μL of OPN standard from the vial was 
added into a tube with 410 μL Assay Diluent A to prepare 18,000 pg/mL 
stock solution of the standard. Finally 400 μl of Assay Diluent A was 
pippeted into each tube. Using the stock standard solution, dilution 
series as shown below was prepared. Each tube was thoroughly mixed 
before the next transfer. Assay Diluent A served as the zero standard (0 
pg/mL). 
 
 
4. The (20x) wash concentrate was checked for any visible crystals and 
mixed gently until dissolved. To 20 mL of wash buffer concentrate 380 
mL of deionized water was added to prepare 400 mL of 1x wash buffer. 
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5. The Detection Antibody vial was given a brief spin before use. 100 μL 
of 1x Assay Diluent B was then added into the vial to prepare a 
detection antibody concentrate. Gentle mixing was done by pipetting up 
and down before use. The detection antibody concentrate was then 
diluted to 80-fold with 1x Assay Diluent B. 
6. After a brief spin of the HRP-Streptavidin concentrate vial gentle 
mixing was done by pipetting up and down before use. HRP 
Streptavidin concentrate was then diluted to 500-fold with 1x Assay 
Diluent B. 
 
Procedure: 
1. All reagents and samples were brought to room temperature (18 - 25°C) 
before use. 
2. 100 μL of each standard and sample was added into appropriate wells 
and incubated for 2.5 hours at room temperature. 
3. The solution was then discarded and washed 4 times with 1x Wash 
Solution (200 μL each). 
4. 100 μL of 1x prepared biotinylated antibody was then added to each 
well and incubated for 1 hour at room temperature. 
5. The solution was discarded and then washed 4 times with 200μL of 1x 
Wash Solution for each well. 
6. 100 μL of prepared Streptavidin solution was then added to each well 
and incubated for 45 minutes at room temperature. 
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7. The solution was then discarded and washed 5 times with 200μL of 1x 
Wash Solution for each well. 
8. 100 μL of TMB one-step substrate reagent was then added to each well 
and incubated for 30 minutes at room temperature. 
9. 50 μL of Stop Solution was then added to each well and read at 450 nm 
immediately. 
 
Calculation of results 
 The standard and sample optical density was subtracted from the zero 
standard optical density. 
 
 The standard curve was plotted with standard concentration on the x-
axis and absorbance on the y-axis and the best-fit straight line was drawn 
through the standard points. The concentration of plasma osteopontin in each 
sample was determined from the standard graph. 
 
STANDARD CONCENTRATION 
(pg/mL) ABSORBANCE 
18000 1.269 
6000 1.1393 
2000 0.8548 
666.7 0.5041 
222.2 0.2698 
74.07 0.2312 
0 0.0142 
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Sensitivity 
 The minimum concentration of OPN detected by the kit was < 50 pg/mL 
.  
Specificity 
 Cross Reactivity: This ELISA kit shows no cross-reactivity with other 
cytokines. 
 
Linearity: up to 18000pg/mL 
ESTIMATION OF SERUM HYALURONIC ACID 
 The serum hyaluronic acid level was estimated using the Sandwich 
Enzyme Linked Immuno Sorbent Assay (ELISA) method (Cusabio). The kit 
was stored at 2-8oC in a refrigerator. 
 
Principle: 
 Quantitative sandwich enzyme immunoassay technique was employed 
for estimation of  serum HA. Antibody specific for HA were pre-coated onto a 
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micro plate. The standards and samples were then pipetted into the wells and 
any HA present in the sample was bound by the immobilized antibody. The 
wells were then washed to remove any unbound substances, then a biotin-
conjugated antibody specific for HA was added to the wells. After washing, 
avidin conjugated Horseradish Peroxidase (HRP) was added to the wells. 
Following a wash to remove any unbound avidin-enzyme reagent, a substrate 
solution was added to the wells and colour developed in proportion to the 
amount of HA bound in the initial step. The colour development was then 
stopped by using a stop solution and the intensity of the colour was measured.  
 
Reagents: 
1. Micro plate for assay (12×8 strips coated micro wells). 
2. 2 vials of freeze dried standard. 
3.  120μL of 100x concentrate of Biotin- antibody 
4.  120μL of 100x concentrate of HRP- avidin 
5.  15 mL of  Biotin-antibody diluent 
6.  15mL  of HRP- avidin diluent 
7.  50mL  of Sample diluent 
8.  20mL of  25 x concentrate Wash buffer   
9.  10mL  of TMB substrate solution 
10.  10 mL of stop solution 
 
 The serum samples were diluted with sample diluent (1:100) before test. 
The suggested 100-fold dilution was achieved by adding 10μL sample to 40μL 
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of sample diluent. The 100-fold dilution was completed by adding 15μL of this 
solution to 285μL of Sample Diluent. 
 
Preparation of reagents and standards: 
Bring all reagents to room temperature (18-25°C) before use.  
1. Biotin-antibody (1x) - The vial was centrifuged before opening.  Biotin-
antibody required a 100-fold dilution. The100-fold dilution was made by 
adding 10 μL of Biotin-antibody with 990 μL of Biotin-antibody 
Diluent.  
2. HRP-avidin (1x) - The vial was centrifuged before opening. HRP-avidin 
required a 100-fold dilution. The100-fold dilution was prepared by 
adding10μL of HRP-avidin to 990μL of HRP-avidin Diluent.  
3.  Wash Buffer(1x)-  The wash buffer was checked for the presence of 
crystals before use, kept at room temperature and mixed gently until the 
crystals have completely dissolved. To 20 mL of (25 x) Wash Buffer 
Concentrate 480mL of deionized water was added to prepare 500 mL of 
(1x) Wash Buffer. 
4. Preparation of standards - The standard vial was centrifuged at 6000-
10,000 rpm for 30s before use.  
 
 The standard was reconstituted with 1.0 mL of Sample diluent. This 
reconstitution provided a stock solution of 10ng/mL. Then the standard was 
mixed to ensure complete reconstitution and the standard was allowed to sit for 
a minimum of 15 minutes with gentle agitation prior to making dilutions. 
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 250μL of sample diluent was then pipetted into each tube (S0-S6).  The 
stock solution was used to produce a 2- fold dilution series.  Each tube was 
thoroughly mixed before the transfer. The undiluted standard served as the high 
standard (10 ng/mL). The sample diluent served as the zero standard (0 
ng/mL). 
 
 Procedure:  
All reagents and samples were brought to room temperature before use. 
1. 100μL of standard and sample were added per well and then incubated 
at 37°C for 2 hours. 
2.  The liquid of each well was removed without washing . 
3. 100μL of Biotin-antibody (1x) was then added to each well and 
incubated at 37°C for 1 hour.  
5. With ELISA washer three washes was performed with Wash Buffer 
200μL for each well. After the last wash, the remaining wash Buffer was 
removed by decanting on a filter paper.  
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6. 100μL of HRP-avidin (1x) was then added to each well and incubated at 
37°C for 1 hour.  
7. The wash process was repeated for five times as in step 5.  
8. 90μL of TMB Substrate was added to each well and incubated at 37°C 
for 15-30 minutes. 
9. 50μL of stop solution was added to each well, the plate was gently 
tapped to ensure thorough mixing.  
10. The optical density of each well was determined within 5 minutes, using 
a micro plate reader set at 450 nm.   
 
Calculation of results 
 A standard curve was constructed by plotting the absorbance for each 
standard on the y-axis against the concentration on the x-axis and a best fit 
curve through the points on the graph was drawn. The data may be linearized 
by plotting the log of the HA concentrations versus the log of the O.D. and the 
best fit line can be determined by regression analysis. 
 
 
STANDARD CONCENTRATION 
(ng/mL) ABSORBANCE 
10 1.7628 
5 1.6773 
2.5 1.0754 
1.25 0.7067 
0.625 0.3947 
0.312 0.2056 
0.156 0.1291 
0 0.0779 
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Detection range - 0.156ng/mL - 10 ng/mL. 
Sensitivity  
 The minimum concentration of human HA that can be detected by the 
kit is < 0.039ng/mL. 
 The sensitivity of the assay, or LOWER LIMIT of DETECTION (LLD) 
was defined as the lowest protein concentration that could be differentiated 
from zero. It was determined the mean O.D value of 20 replicates of the zero 
standard added by their three standard deviations. 
 
Specificity  
 This assay has high sensitivity and excellent specificity for detection of 
human HA. No significant cross-reactivity or interference between human HA 
and analogues was observed. 
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ESTIMATION OF SERUM CALCIUM AND PHOSPHORUS 
 The estimation of serum calcium and phosphorus was done to know the 
relationship of these parameters besides the radiological grades in patients with  
knee OA and to rule out secondary causes of OA. 
 
Estimation of serum calcium 
 Serum calcium was estimated in the samples using Accucare Calcium 
Arsenazo III method in MERCK semi autoanalyzer. 
 
Principle: 
 At neutral pH, calcium reacts with Arsenazo III (1,8- dihydroxy-3,6-
disulpho-2,7-naphthalene-bis(azo)-dibenzenearsonic acid), it forms a blue 
coloured complex. The intensity of the colour formed is proportional to the 
calcium concentration in the sample. 
 
Reagent Composition: 
 Reagent 1 - Arsenazo III reagent 
 Calcium standard  - 10 mg/dL 
 
Method: 
 Arsenazo III method, End point assay. 
 
Assay Procedure: 
 The assay was performed after calibration. The standard used was 
10mg/dL. 25 μL of the sample was added to 1000 μL of the reagent, mixed 
well and incubated at room temperature for 5 min. Final absorbance of the 
67 
 
sample (Ac) and standard (As) against the reagent blank was measured at 650 
nm. 
 
Calculation: 
 Serum/Plasma = (Ac) sample × Standard concentration 
                                        (As) standard 
Linearity: 
              The kit is linear up to 16 mg/dL. 
 
Reference Values: 
          Serum: 8.8 – 10.2 mg/dL  
 
Estimation of phosphorus 
 Serum phosphorus was estimated in the samples using pathozyme 
phosphorus molybdate U.V. method in MERCK semi autoanalyzer. 
 
Principle: 
 When inorganic phosphorus reacts with ammonium molybdate in an 
acidic medium it forms a phosphomolybdate complex, which can be measured 
in the U.V. range at 340 nm. The absorbance of this complex is directly 
proportional to the amount of inorganic phosphorus present in the sample. 
 
Reagent Composition: 
 Molybdate Reagent                    
 Phosphorus standard: 5 mg/dL 
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Method: 
 Molybdate U.V method, End point assay 
 
Procedure: 
 The assay was performed after calibration. The standard used was 
5mg/dL. 10 μL of the sample was added to 1000 μL of the reagent, mixed well 
and incubated for 5 min at room temperature and the absorbance of the 
standard (Abs.S) and the test sample (Abs.T) against the reagent blank (Abs.B) 
was measured at 340 nm. 
 
Reference Values: 
 Serum Adults : 2.5 – 5.0 mg/dL 
 Serum Children : 4.0 – 6.5 mg/dL 
 
Calculation: 
 Phosphorus in mg/dL =   (Abs.T)-(Abs.B)     × 5 
                                         (Abs.S)-(Abs.B) 
Linearity: 
 The kit is linear upto 20 mg/dL.  
 
  
Statistical analysis 
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STATISTICAL ANALYSIS 
 
 Statistical analysis was performed for the present study using the 
“statistical package for social sciences (SPSS) software”. Student's t-test was 
performed for comparison between groups. Pearson's correlation coefficient 
was employed to determine the correlation among the concentration of plasma 
osteopontin and serum hyaluronic acid   and the Kellgren-Lawrence (K/L) 
grades. P-values <0.05 were considered statistically significant. 
 
1. Continuous variables age, height, weight, BMI, the concentrations of 
calcium, phosphorus, OPN & HA in cases and controls were compared by 
student “t” test. 
2. The gender distribution between cases and controls was compared using 
chi-square test. 
3.  OPN level with various Kellgren-Lawrence( K/L) grades  of OA was 
compared using ANOVA. 
4.  HA level with various K/L grades of OA was compared using ANOVA. 
5. Pearson correlation was used to measure the strength of relationship 
between OPN, HA and K/L grading. 
6. Pearson correlation was used to assess the relationship between OPN and 
HA. 
7. ROC curve was used to analyse the diagnostic value of OPN and HA for 
OA. 
 
 
Results 
  
Height Weight BMI SBP DBP K/L grade OPN HA Calcium Phosphorus
(cm) (kg) (kg/m2) (mmHg) (mmHg) (pg/mL) (ng/mL) (mg/dL) (mg/dL)
1 52 Female 150 65 28.88 120 70 3 770.6 2.434 9.3 3.7
2 60 Female 155 60 25 120 70 3 808.2 2.525 9.8 4.3
3 38 Female 152 65 28.13 110 70 2 790.2 2.429 9.1 3.1
4 62 Female 155 62 25.83 140 80 4 4090 3.346 9.2 4.5
5 60 Female 150 75 33.33 130 80 3 990.4 2.371 9.3 3.6
6 54 Female 154 70 29.53 130 80 3 1462 2.419 9.5 4.4
7 52 Female 154 85 35.86 130 80 3 1489 1.75 9.4 4.1
8 50 Female 154 60 25.31 100 70 2 570 2.27 9.7 3.7
9 55 Female 151 87 38.16 130 80 3 1490 2.31 9.2 4.3
10 65 Female 150 55 24.44 110 70 3 1120 2.513 9.5 4.4
11 51 Female 154 70 29.53 110 70 4 1532 3.388 9.4 4.3
12 40 Female 152 65 28.13 100 60 3 522.5 3.471 9.3 4.4
13 56 Female 150 55 24.44 120 70 4 1038 1.921 9.8 4.8
14 63 Female 150 65 28.88 130 80 2 410.4 2.215 9.6 4.4
15 40 Female 152 55 23.8 110 70 3 1104 0.897 9.2 4.1
16 48 Female 152 55 23.8 100 60 3 490.8 3.136 9.9 4.3
17 58 Female 150 60 26.66 110 70 4 344.8 2.844 9.5 4.2
18 65 Female 150 50 22.22 100 70 4 855 2.389 9.6 4
19 53 Female 148 55 25.11 120 70 3 919.1 2.539 9.8 4.3
20 60 Female 154 55 23.2 120 70 4 787.3 3.056 9.4 4.5
21 57 Female 148 52 23.74 130 70 2 643.2 1.744 9.1 4.3
22 51 Female 155 59 24.58 140 76 2 521.1 1.221 9.6 4.1
23 65 Female 153 67 28.63 110 74 3 372.3 2.518 9.7 4.4
24 55 Female 155 62 25.83 130 74 3 961.1 2.297 9.2 3.6
25 50 Female 151 75 32.89 120 70 3 657.4 2.455 9.4 3.5
26 75 Female 145 50 23.8 130 80 3 602.9 2.169 9.5 3.9
27 60 Female 149 50 22.52 110 70 4 1847 3.333 9.2 4.1
28 45 Female 151 52 22.8 100 70 2 555.3 1.813 9.8 3.6
29 55 Female 154 50 21.09 130 84 3 745.3 3.16 9.1 3.9
30 53 Female 156 57 23.45 110 74 4 747.1 2.746 9.5 4.5
MASTER CHART OF PATIENTS WITH OA KNEE
Age in yearsCASES Sex
Height Weight BMI SBP DBP K/L grade OPN HA Calcium Phosphorus
(cm) (kg) (kg/m2) (mmHg) (mmHg) (pg/mL) (ng/mL) (mg/dL) (mg/dL)
31 52 Female 154 55 23.2 140 80 3 651.7 2.274 9.7 3.5
32 53 Female 160 75 29.29 120 74 3 455.5 5.31 9.4 3.6
33 55 Female 153 85 36.32 130 84 3 605.1 2.388 9.6 3.7
34 50 Female 152 54 23.37 120 74 4 887.1 3.068 9.3 4.5
35 40 Female 149 58 26.12 100 70 4 1779 2.855 9.7 4.1
36 60 Female 151 59 25.87 130 80 3 932.1 4.125 9.5 4.2
37 55 Female 152 65 28.13 110 74 3 574 3.664 9.8 4
38 60 Female 150 50 22.22 130 80 3 780.4 1.05 9.6 4.2
39 50 Female 155 65 28.08 120 74 3 471.8 2.43 9.2 4
40 47 Female 151 60 26.31 130 74 3 260.5 4.489 9.3 4.2
41 50 Female 156 59 24.27 110 74 3 805 1.832 9.1 4.1
42 60 Female 153 67 28.63 100 70 3 1478 1.444 9.6 4.5
43 65 Female 155 57 23.75 120 74 3 964.2 2.523 9.4 4.4
44 53 Female 153 53 22.64 120 74 3 888.3 3.601 9.5 3.7
45 63 Female 156 66 27.16 130 74 3 622.6 4.815 9.3 3.7
46 65 Male 168 82 29.07 140 80 2 531.1 1.882 9.6 3.9
47 62 Male 164 66 24.53 130 80 4 929.3 3.377 9.4 3.6
48 73 Male 165 69 25.36 120 84 3 581 3.442 9.6 4.5
49 70 Female 152 58 25.1 120 70 2 517.2 0.942 9.5 4.2
50 55 Male 162 53 20.22 130 80 2 487.9 1.16 9.3 3.9
51 53 Male 157 74 30.08 130 86 3 530.1 2.064 9.4 3.5
52 57 Male 165 60 22.05 140 80 3 1294 2.231 9.7 3.6
53 65 Male 172 75 25.33 130 84 3 4541 4.16 9.3 3.8
54 59 Male 168 72 25.53 120 70 3 1037 2.704 9.5 3.7
55 65 Male 165 80 29.41 130 80 3 441.2 1.961 9.2 4.1
56 60 Male 169 68 23.85 110 74 4 749.2 3.109 9.6 3.7
57 56 Male 172 73 24.74 140 80 3 738.8 1.463 9.2 3.6
58 60 Male 166 64 23.27 120 74 3 705.9 1.902 9.7 4.5
59 70 Female 160 55 21.48 130 80 4 986.7 2.768 9.6 3.8
60 65 Female 158 52 20.88 120 74 4 3632 2.263 9.4 4
CASES Age in years Sex
CONTROLS Age in Sex Height Weight BMI SBP DBP K/L grade OPN HA Calcium Phosphorus
years (cm) (kg) (kg/m2) (mmHg) (mmHg) (pg/mL) (ng/mL) (mg/dL) (mg/dL)
1 61 Female 162 53 20.15 110 74 . 783.7 2.665 9.6 4.3
2 60 Female 150 52 23.11 100 70 . 540.1 1.245 9.4 3.7
3 65 Female 155 60 25 120 70 . 503.1 1.57 9.9 3.9
4 55 Female 156 63 25.92 130 80 . 658.2 2.959 9.5 4.2
5 60 Female 164 56 20.82 110 70 . 541.6 2.062 9.3 3.8
6 48 Female 159 55 21.74 100 70 . 532.1 1.682 9.2 3.9
7 55 Female 161 60 23.16 120 74 . 655.9 2.224 9.8 3.6
8 56 Female 160 58 22.65 110 70 . 596.5 1.983 9.9 4.3
9 38 Female 158 52 20.88 130 80 . 596.5 1.948 9.7 3.6
10 54 Female 162 54 20.61 120 70 . 613.3 1.151 9.6 3.8
11 63 Female 159 58 22.92 100 70 . 739.9 1.484 9.3 4.3
12 55 Female 161 64 24.71 110 70 . 397.3 1.767 9.4 3.7
13 45 Female 164 60 22.3 120 80 . 607.7 1.75 9.3 4.4
14 50 Female 162 55 20.99 130 70 . 770.1 1.681 9.5 3.6
15 55 Male 168 58 20.56 120 74 . 576.7 1.586 9.6 3.8
16 65 Male 170 64 22.14 140 80 . 983.7 2.204 9.1 4.4
17 51 Female 157 58 23.51 110 74 . 980.3 2.279 9.7 4.2
18 70 Female 162 61 23.38 130 80 . 522.2 2.514 9.2 3.8
19 65 Female 164 58 21.64 120 74 . 923.5 1.806 9.3 3.6
20 60 Female 156 62 25.51 100 70 . 607 1.547 9.4 4.1
21 40 Female 164 60 22.38 120 70 . 250.6 0.854 9.6 3.9
22 53 Male 168 68 24.11 130 74 . 500.5 2.271 9.8 4.2
23 62 Male 166 62 22.54 110 70 . 519.4 1.239 9.9 4
24 57 Male 168 64 22.69 130 80 . 919.2 2.024 9.5 3.6
25 75 Female 160 56 21.87 120 70 . 466.8 2.528 9.9 4.1
26 47 Female 163 62 23.39 110 80 . 990.9 1.461 9.3 4.4
27 53 Female 162 57 21.75 100 70 . 655.5 2.369 9.6 4.2
28 50 Female 158 60 24.09 130 80 . 248.9 2.018 9.5 3.7
29 60 Male 164 65 24.25 120 74 . 398.7 1.56 9.8 4.3
30 72 Male 169 68 23.86 140 80 . 251.6 1.841 9.6 3.6
MASTER CHART OF CONTROLS
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RESULTS 
TABLE – 1 
 Age distribution of patients among cases (OA knee) and controls 
 Group N Mean 
Std. 
Deviation P value 
Age in 
years 
Control 30 56.67 8.683 
0.971  
Cases 60 56.60 7.907 
  
 In the present study 60 patients with varying grades of OA, confirmed 
by X-ray knee joint and 30 controls, were enrolled. The mean and standard 
deviation of OA patients and controls were 56.60+/-7.907 and 56.67+/-8.683 
respectively. There was no statistical difference in the age between OA patients 
and controls (p=0.971).  
 
TABLE-2  
Gender distribution among patients with OA knee and controls 
 Controls Cases p-value 
Males 7 12 
 
0.715 
36.8% 63.2% 
Females 23 48 
32.4% 67.6% 
                     
  The above gender distribution among patients with OA knee and 
controls show that females constitute higher percentage than males in both 
cases and controls. There is no significant difference in gender among cases 
and controls (p=0.715).  
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Comparison of patient characteristics 
 
TABLE - 3 
Group N Mean Std. Deviation P value 
Height Control 30 161.73 4.571 
0.123  
Cases 60 155.28 6.325 
Weight Control 30 59.43 4.305 
<0.001**  
Cases 60 62.87 9.675 
BMI Control 30 22.7543 1.51611 <0.001** Cases 60 26.0972 3.77687 
** HIGHLY SIGNIFICANT 
 
TABLE - 4 
 Group N Mean Std. Deviation P value 
SBP 
Control 30 118.00 11.861 
0.234  
Cases 60 121.17 11.802 
DBP 
Control 30 73.93 4.346 
0.458  
Cases 60 74.80 5.575 
 
 
 Table-3 & Table-4 compares the mean, standard deviation and p-value 
of cases and controls with respect to variables height, weight, BMI, systolic 
and diastolic BP.  There is a highly statistically significant difference with 
respect to weight and BMI (p=<0.001**) among cases and controls, while there 
is no significant difference among cases and controls with respect to height, 
systolic and diastolic BP. 
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TABLE – 5  
Comparison of calcium and phosphorus levels among cases and controls 
 
 Table-5 shows the mean, standard deviation and p-value of the analytes 
- calcium and phosphorus. The mean and standard deviation of calcium and 
phosphorus of patients with OA knee and controls are 9.46+/-.21,9.54+/-.23 
and 4.03+/-.35,3.97+/-.28 respectively. There is no statistically significant 
difference among cases and controls with respect to calcium and phosphorus 
(p-value .105 and .365 respectively). 
  
 Group N Mean 
Std. 
Deviation P value 
Calcium 
Control 30 9.540 0.2328 
0.105 
Cases 60 9.460 0.2109 
Phosphorus 
Control 30 3.967 0.2881 
0.365 
Cases 60 4.035 0.3569 
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TABLE – 6 
Comparison of concentration of OPN & HA in patients with OA knee 
(cases) and controls 
 
 Group N Mean Std. Deviation P value 
OPN 
Control 30 611.050 207.5941 
0.014* 
Cases 60 984.912 804.0174 
HA 
Control 30 1.87573 0.480887 
<0.001** 
Cases 60 2.58292 0.908696 
 
** HIGHLY SIGNIFICANT 
*SIGNIFICANT       
 
 In Table-6., the mean and standard deviation of the OPN values in 
patients with OA knee and controls are tabulated. The mean OPN concentration 
in patients with OA knee was 984.91+/−804pg/mL while in controls it was 
611.05+/−207.59 pg/mL. The difference in OPN values between OA knee 
patients and controls was statistically significant (p=0.014) as shown in 
Graph1. 
 
 Table-6 shows the mean and standard deviation for the values of HA 
among the cases and controls. The mean HA in OA knee patients was 
2.58+/−0.90ng/mL while in controls it was 1.87+/−0.48 ng/mL. There was a 
highly significant difference in the value of HA in cases and controls with a p-
value of <0.001** as shown in Graph-2.  
 
  
GRAPH-1 
 
Comparison of concentration of OPN in 
patients with OA knee (cases) and controls 
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Comparison of concentration of HA in patients with  
OA knee (cases) and controls 
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TABLE-7  
Comparison of OPN levels with various K/L grades of OA among cases 
 
K/L-
GRADE N 
Osteopontin(pg/mL) 
p- value 
95%Confidence 
Interval for Mean 
Mean Std. Deviation 
 
Lower 
Bound 
Upper 
Bound 
 
2 9 558.489 107.1066 
 
0.022* 
 
476.159 640.818 
3 37 915.238 693.5673 683.991 1146.485 
4 14 1443.179 1108.5290 803.133 2083.224 
*SIGNIFICANT 
K/L Grade- 2,3,4 & OPN level 
 
 Table-7 shows the comparison of plasma osteopontin levels in relation 
to radiological K/L grading of OA in the present study and it was found that the 
mean plasma OPN levels in K/L grades 2, 3 & 4 were 558.48+/−107.10pg/mL, 
915.238+/−693.56pg/mL and 1443.179+/−1108.52pg/mL This implies that the 
plasma OPN levels were significantly higher in K/L grades 2, 3 & 4(p=0.022) 
as shown in Graph-3.  
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Comparison of OPN levels with various K/L grades of OA among cases 
 
                                                 
 
 
 
 
 
558
915
1443
0
200
400
600
800
1000
1200
1400
1600
1800
Grade  2 Grade  3 Grade  4
O
PN
 co
nc
en
tr
at
io
n 
(p
g/
m
L)
K/L GRADE
75 
 
 
TABLE-8 
Comparison of HA levels with various K/L grades of OA among cases 
 
K/L-
GRADE N 
Hyaluronic 
acid(ng/mL)Mean 
Std. 
Deviation p-value 
95% Confidence 
Interval for 
Mean 
Lower 
Bound 
Upper 
Bound 
 
2 9 1.74178 0.530247 
0.006** 
1.33419 2.14936 
3 37 2.67124 0.998217 2.33842 3.00407 
4 14 2.89021 0.448811 2.63108 3.14935 
 
K/L Grade- 2,3,4 & HA level,        ** Highly significant 
 
 Table-8 shows the comparison of serum HA levels in relation to 
radiological K/L grading of OA in the present study and it was found that the 
mean serum HA levels in K/L grades 2, 3 & 4 were1.74+/−0.53 ng/mL, 
2.67+/−0.99ng/mL and 2.89+/− 0.44ng/mL .This implies that the serum HA 
levels were significantly higher in K/L grades 2, 3 & 4 (p=0.006) as shown in 
Graph-4. 
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Comparison of HA levels with various K/L grades of OA among cases 
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TABLE-9 
 Pearson correlation coefficient between OPN, HA and K/L grade in the 
study population 
  K/L grade 
OPN 
Pearson Correlation 0.349(**) 
Sig. (2-tailed) 0.006** 
N 60 
HA 
Pearson Correlation 0.358(**) 
Sig. (2-tailed) 0.005** 
N 60 
 
** Correlation is significant at the 0.01 level (2-tailed). 
 
 Table-9 shows the Pearson correlation coefficient on variables OPN and 
K/L grade. In order to measure the strength of linear relationship between OPN 
and K/L grade, Pearson correlation was done and it was observed that there 
was a positive linear relationship between OPN and K/L grade with r=0.349, p-
value=0.006 
 
 Pearson correlation coefficient was done on variables HA and K/L grade 
in order to measure the strength of linear relationship between the two variables 
as tabulated. It was observed that as K/L grade increases the concentration of 
HA also increases, indicated by a positive linear relationship with r=0.358, p-
value=0.005 
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TABLE-10  
Pearson correlation coefficient between OPN and HA in the study 
population 
 
 
 Table-10 shows the Pearson correlation coefficient between the 
variables OPN and HA. This was done to find out whether there is any linear 
relationship between these variables. In the present study it was found that 
there was no statistical significance p-value=0.256.  
 
  
  HA 
OPN 
Pearson Correlation 0.149 
Sig. (2-tailed) 0.256 
N 60 
78 
 
ROC curve of OPN for analysis of the diagnostic values of plasma OPN in 
OA patients 
 
AREA UNDER THE CURVE - OPN 
Area 
Std. 
Error(a) 
Asymptotic 
Sig.(b) 
Asymptotic 95% 
Confidence Interval 
0.683 0.056 0.005 0.572 0.793 
 
According to the data of 60 patients with varying grades of OA knee and 
30 normal subjects as controls ROC curve was plotted. When 617.95pg/mL 
was set as cut-off level of plasma OPN, the sensitivity to predict susceptibility 
of patients for developing OA knee was 67% and the specificity was 63%.The 
area under the curve for OPN was 0.683. Hence OPN can be used as a 
biomarker to assess the severity of OA knee. 
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ROC curve for HA for analysis of the diagnostic values of serum HA in 
OA patients  
 
                     
 AREA UNDER THE CURVE - HA 
 
 When  2.06ng/mL was set as the cut-off level of serum HA, the 
sensitivity to predict patients with OA knee was 75% and the specificity was 
70%. The area under the curve (AUC) was 0.761 for HA . This implies that HA 
can be used as a biomarker to assess the cartilage damage in OA knee. 
 
  
Area Std. Error(a) 
Asymptotic 
Sig.(b) 
Asymptotic 95% 
Confidence Interval 
0.761 0.051 0.000 0.662 0.860 
Discussion 
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DISCUSSION 
 
 OA knee is a chronic degenerative disease with multiple pathogenic 
pathways of chondrocyte triggering and downstream transcription factors, 
which leads to final common pathway of activation of MMP-13 mediated type-
II collagen breakdown which ultimately causes cartilage erosion. OPN also has 
a crucial role in MMP-13 activation leading to cartilage destruction and release 
of HA from the cartilage. Finally impairment of regenerative capacity of the 
cartilage occurs due to cell death caused by deranged autophagy169 (as shown 
in the figure below). Till date only plain x-rays are available to assess the 
severity of OA in the knee joint. Recently newer biomarkers on detecting 
cartilage matrix synthesis and degradation are gaining clinical importance in 
the diagnosis of severity of OA knee and also recent advances in the 
proteomics and microRNA have enabled detection of newer OA biomarkers. 
 
                               Pathways of OA cartilage pathology 
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 In the present study, the plasma concentration of OPN was evaluated to 
assess its utility as a biological marker in patients with OA knee and to 
correlate with radiological grade and to assess, if osteopontin contributes to the 
pathogenesis of the degenerative process of osteoarthritis by stimulating 
MMP13 and thereby increasing hyaluronic acid levels in the serum in patients 
with OA knee. 
 
 Insignificant p-values were obtained for variables viz., age, gender, 
height, systolic and diastolic BP while comparing the cases and controls. This 
implies that the cases and controls were perfectly matched with respect to the 
confounding variables. There is a statistically significant difference among 
cases and controls with respect to weight and BMI. This indicates that obesity 
has a significant role in pathogenesis of OA knee. 
 
 The common secondary causes of OA knee- post traumatic was ruled 
out by history and the other most common cause the calcium pyrophosphate 
deposition (CPPD) disease in elderly by estimation of calcium and phosphorus. 
In this study the levels of serum calcium and phosphorus were normal in both 
the cases and controls implying that the secondary causes of OA in the study 
groups has been excluded. 
 
 In this study the plasma OPN concentrations were significantly higher in 
patients with OA knee when compared to controls. Significant differences in 
OPN concentrations were observed among the cases when they were classified 
into three groups (K/L grade2, 3 &4) based on their radiological findings. An 
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increase in concentration of plasma OPN with advancing radiological grade 
was observed among the patients with OA knee. The OPN levels did not vary 
significantly with gender in both the study groups in this study. Also a positive 
correlation was observed between OPN and K/L grade in this study indicating 
that as K/L grade advances the OPN concentration also increases. Hence 
plasma OPN level  significantly correlates with the severity of the disease. 
Similar results were obtained by Honsawek et al126. Increase in OPN level 
among cases when compared to controls and increase in osteopontin levels 
with radiological grade 3 and 4 when compared to K/L grade 2 were also 
observed by Honsawek et al126. 
 
 HA is produced by cells of ECM and is thought to play a role in cell 
signalling170. Degradation and turnover of ECM results in the release of HA 
and its fragments into the systemic circulation and endocytosis via a specific 
HA receptor141 and they are cleared by the liver and lymphatics. Increased HA 
concentration in the inflamed synovium has been suggested to contribute to 
joint stiffness & edema in the arthritic joint143. The synovial inflammation and 
cartilage degradation result in the release of HA into the circulation there by 
increasing the serum levels. Hence serum HA measurements maybe used to 
assess the amount of cartilage damage in OA knee. 
 
 In the present study the serum HA concentrations were significantly 
higher in patients with OA knee when compared to controls. Significant 
differences in HA concentrations were observed among the cases when they 
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were classified into three groups (K/L grade2,3&4) based on their radiological 
findings. An increase in concentration of serum HA with advancing 
radiological grade was observed among the patients with OA knee. This 
increase in HA level with radiological grade was statistically significant. The 
HA levels did not vary significantly with gender in both the study groups in 
this study. Also a positive correlation was observed between HA and K/L grade 
in this study indicating that as K/L grade advances the HA concentration also 
increases. Hence HA levels significantly correlates with the severity of the 
disease and the amount of cartilage damage. Similar result was reported by 
Sharif et al171- increased serum HA levels was observed in patients with late 
stages of OA than in patients with early stages of OA. A positive correlation 
was demonstrated between serum HA level and the amount of involved 
cartilage by another study172.  
 
 Hence in the present study statistically significant increase in 
concentration of both OPN & HA with respect to radiological grade and a 
positive correlation between OPN and K/L grade & HA and K/L grade implies 
that OPN has a significant role in activating MMP-13 causing degradation of 
articular cartilage and release of HA into the circulation in osteoarthritis. Hence 
OPN and HA can be used in combination as biomarkers to assess the severity 
of the disease. 
 
 In the present study the correlation between OPN and HA did not show 
any statistical significance implying that HA level increase is contributed by 
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many factors other than OPN. OPN and many inflammatory mediators are 
stimulated in OA knee by various pathways but finally they merge to stimulate 
MMP-13 which causes destruction of the cartilage thereby releasing HA in 
systemic circulation.    
 
 In the present study analysis of diagnostic value of plasma OPN and 
serum HA was done by plotting Receiver Operator Characteristic (ROC) curve. 
Hence both increase in plasma OPN (cut-off value-617.95pg/mL) and increase 
in serum HA (cut-off value 2.06ng/mL) can be used as biomarkers to assess the 
severity of the disease and cartilage damage in patients with OA knee. 
  
Conclusion 
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CONCLUSION 
 
 OA knee is a chronic degenerative joint disease leading to joint 
disability. The disease is emerging as a major health problem and a threat to 
normal healthy life in recent years. Early diagnosis of OA may help to 
overcome this problem. For this biomarkers carefully chosen based on our 
knowledge on pathogenic mechanisms, can be used to predict and assess the 
severity of OA cartilage. This can help in modulating drug therapy against the 
specific pathogenic pathway. Till now only x-rays are in use to assess the 
severity of OA in the knee joint. OPN and HA are the two biomarkers 
evaluated in the present study to assess the disease progression in OA knee 
joint. 
 
 In the present study there was a significant higher concentrations of 
OPN and HA in patients with OA knee than in the controls. The concentration 
of OPN and HA increases as the radiological grade increases while the gender 
differences cause no significant changes. Hence OPN and HA can be used as 
biomarkers to assess the disease progression and cartilage damage respectively. 
 
 Extensive analysis of different set of markers in large number of patients 
with OA knee and following them prospectively may help in identifying the 
markers that are independent predictors of outcome. These biomarkers may 
serve as a good target for development of drugs to treat OA in the near future. 
                                 
  
Limitation of the study 
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LIMITATIONS OF THE STUDY 
1. The sample size was not large enough to arrive at definitive conclusions. 
2.  The investigation was performed on only those patients who attended 
Orthopaedics Out-patient department, Rajiv Gandhi Government General 
Hospital, a tertiary care centre, for evaluation or treatment of knee OA 
which might not be true representative of patient presenting with OA knee.  
3. An important critical issue that limit the use of osteopontin as a specific 
marker for osteoarthritis is that the osteopontin level is also increased in a 
variety of cancers.  
4. The determination of an accurate cut-off value for circulating osteopontin 
level is another critical issue in its clinical application. Further studies with 
standardized assay system in a large population are required to gain insight 
into the potential utility of osteopontin.  
 
  
Scope for further studies 
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FUTURE PROSPECT OF THE STUDY 
 
 In OA knee all the major pathogenic mechanisms that cause destruction 
of cartilage finally merge into one common pathway i,e. stimulation of the 
Matrix Metalloproteinase-13(MMP-13) which ultimately causes destruction of  
the cartilage. Hence study can be planned to estimate MMP-13 levels among 
OA patients and controls to assess the prognostic efficacy of the same in the 
future to assess the disease progression.  
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Annexures 
   
  
INFORMATION SHEET 
 
Title: Correlation of plasma osteopontin with radiological grading in 
patients with osteoarthritis in the knee joint.  
 
Investigator                         :    Dr.P.Nirmaladevi 
    Post Graduate, 
    Institute of Biochemistry, 
    Madras Medical College, 
    Chennai- 600 003. 
 
Guide                                   :   Dr. R. Chitraa, 
                                   Professor, 
                                          Institute of Biochemistry, 
                                          Madras Medical College, 
                                          Chennai- 600 003. 
 
Osteoarthritis is a universal and most common joint disease affecting both 
males and females equally. Hence to identify patients with a high risk for 
destructive OA and to monitor drug efficacy more sensitive techniques than 
plain X- ray are needed. The purpose of the present study is to correlate 
concentration of osteopontin levels in plasma of patients with knee 
osteoarthritis and to evaluate the possible correlation with the radiographic 
grading of knee osteoarthritis. 
 
Hence I am doing this study titled “Correlation of plasma osteopontin with 
radiological grading in patients with osteoarthritis in the knee joint” 
attending Rajiv Gandhi Govt. General Hospital, Chennai. To do this study , I 
need to collect 6ml of blood from 60 knee osteoarthritis patients and 30 healthy 
subjects, while collecting blood there will not be any side effects. 
 
Your identity will be confidential throughout the study and during publication 
or presentation in any clinical journals. 
 
Participation in this study is purely voluntary. You can withdraw from  the 
study at any time. Your decision will not result in any loss of  benefits to which 
you are otherwise entitled. The results of the study will be intimated to you. 
Kindly sign in this information sheet and consent form, if you have willingness 
to participate in this study, 
 
 
Signature of investigator                                               Signature of participant 
Place:                                                                              Thumb Impression 
Date: 
  
PATIENT CONSENT FORM 
TITLE OF THE STUDY : CORRELATION OF PLASMA OSTEOPONTIN 
WITH RADIOLOGICAL GRADING IN PATIENTS WITH 
OSTEOARTHRITIS IN THE KNEE JOINT". 
Name :       Date  : 
Age :       OP No  
Sex :       Project Patient No : 
Documentation of the informed consent 
I _____________________________ have read the information in this form (or it has 
been read to me). I was free to ask any questions and they have been answered. I 
hereby give my consent to be included as a participant in “CORRELATION OF 
PLASMA OSTEOPONTIN WITH RADIOLOGICAL GRADING IN 
PATIENTS WITH OSTEOARTHRITIS IN THE KNEE JOINT”. 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator.  
5. I have been informed the investigator of all the treatments I am taking or have 
taken in the past ________ months including any native (alternative) treatment. 
6. I have been advised about the risks associated with my participation in this study. 
7. I agree to cooperate with the investigator and I will inform him/her immediately if 
I suffer unusual symptoms. 
8. I have not participated in any research study within the past ________ month(s). 
9. I am aware of the fact that I can opt out of the study at any time without having to 
give my reason and this will not affect my future treatment in this hospital. 
10. I am also aware that the investigator may terminate my participation in the study 
at any time, for any reason, without any consent. 
11. I hereby give permission to the investigators to release the information obtained 
from me as result of participation in this study to the sponsors, regulatory 
authorities, Govt. agencies, and IEC. I understand that they are publicly presented. 
12. I have understood that my identity will be kept confidential if my data are publicly 
presented. 
13. I have had my questions answered to my satisfaction. 
14. I have decided to be in the research study. 
 
I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form I attest that the information given in this 
document has been clearly explained to me and understood by me, I will be given a 
copy of this consent document. 
 
  
For  participants: 
Name and signature / thumb impression of the participant (or legal representative if 
participant  in competent/For age 10-17 yrs-Name& signature of the parent/guardian.) 
 
Name ______________________________ Signature___________  Date_________ 
 
Name and Signature of impartial witness (required for illiterate patients): 
 
Name ______________________________ Signature___________  Date_________ 
 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining consent: 
 
Name ______________________________ Signature___________  Date_________ 
                          
 
 
 

   
PROFORMA 
Date:                                Sample no:                                Case/Control: 
Name                                   ꞉  
Age/Sex    ꞉  
OP/IP No ꞉  
Address     ꞉  
Height                                          ꞉  
Weight ꞉  
Body Mass Index ꞉  
Diagnosis ꞉  
Chief presenting complaints ꞉  
Pain in the knee joint ꞉  
Duration ꞉  
Swelling over knee ꞉  
Tenderness ꞉  
Crepitus ꞉  
Effusion                                        ꞉  
Muscle wasting                             ꞉  
Limited mobility                           ꞉  
Any other serious medical illness ꞉  
Past History ꞉  
Diabetes                                   ꞉  
Hypertension                               ꞉  
Personal History                         ꞉  
Smoking Duration                        ꞉  
Alcoholism Duration                     ꞉  
Family History                             ꞉  
 
On Examination                           ꞉  
 
                             Conscious ,Oriented 
                               Pallor 
                               Icterus 
                               Pedal  oedema 
                               Knee swelling 
                              Mobility 
                              Tenderness 
Vitals:           PR:                    BP: 
                              CVS: 
                              RS: 
                              Abdomen: 
DIAGNOSIS: 
   
         
INVESTIGATIONS: 
Serum calcium 
Serum phosphorus 
Plasma osteopontin 
Serum hyaluronic acid  
X-ray knee joint - antero-posterior view 
 
 
 
 
 
